CN1298446A - Vaccine containing recombinant pilin and used for resisting neisseria gonorrhoeae or neisseria meningitidis - Google Patents
Vaccine containing recombinant pilin and used for resisting neisseria gonorrhoeae or neisseria meningitidis Download PDFInfo
- Publication number
- CN1298446A CN1298446A CN99805601A CN99805601A CN1298446A CN 1298446 A CN1298446 A CN 1298446A CN 99805601 A CN99805601 A CN 99805601A CN 99805601 A CN99805601 A CN 99805601A CN 1298446 A CN1298446 A CN 1298446A
- Authority
- CN
- China
- Prior art keywords
- pilin
- dna
- class
- sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010000916 Fimbriae Proteins Proteins 0.000 title claims abstract description 421
- 229960005486 vaccine Drugs 0.000 title claims abstract description 82
- 241000588650 Neisseria meningitidis Species 0.000 title claims abstract description 54
- 241000588652 Neisseria gonorrhoeae Species 0.000 title claims abstract description 43
- 230000001580 bacterial effect Effects 0.000 claims description 86
- 150000001413 amino acids Chemical class 0.000 claims description 62
- 239000013612 plasmid Substances 0.000 claims description 61
- 235000001014 amino acid Nutrition 0.000 claims description 60
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 56
- 108090000623 proteins and genes Proteins 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 51
- 230000003053 immunization Effects 0.000 claims description 44
- 238000002649 immunization Methods 0.000 claims description 44
- 239000002671 adjuvant Substances 0.000 claims description 42
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 claims description 34
- 235000018102 proteins Nutrition 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 33
- 239000002773 nucleotide Substances 0.000 claims description 28
- 125000003729 nucleotide group Chemical group 0.000 claims description 28
- 238000000926 separation method Methods 0.000 claims description 24
- 231100000765 toxin Toxicity 0.000 claims description 24
- 206010008631 Cholera Diseases 0.000 claims description 23
- 238000012545 processing Methods 0.000 claims description 19
- 239000003053 toxin Substances 0.000 claims description 18
- 108700012359 toxins Proteins 0.000 claims description 18
- 230000035800 maturation Effects 0.000 claims description 15
- 238000000746 purification Methods 0.000 claims description 10
- 238000002105 Southern blotting Methods 0.000 claims description 9
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 9
- 230000028993 immune response Effects 0.000 claims description 8
- 230000001681 protective effect Effects 0.000 claims description 6
- 238000001890 transfection Methods 0.000 claims description 5
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 30
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 10
- 238000009396 hybridization Methods 0.000 claims 6
- 241000193830 Bacillus <bacterium> Species 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 abstract description 74
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 74
- 101150002077 pilE gene Proteins 0.000 abstract description 64
- 101001059401 Moraxella bovis Type IV major alpha-pilin Proteins 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 description 150
- 210000004027 cell Anatomy 0.000 description 143
- 241000894006 Bacteria Species 0.000 description 75
- 108020004414 DNA Proteins 0.000 description 60
- 244000052616 bacterial pathogen Species 0.000 description 59
- 229940024606 amino acid Drugs 0.000 description 40
- 210000002966 serum Anatomy 0.000 description 40
- 241000699666 Mus <mouse, genus> Species 0.000 description 35
- 238000002965 ELISA Methods 0.000 description 33
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 28
- 241000588724 Escherichia coli Species 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 26
- 239000000047 product Substances 0.000 description 25
- 230000000968 intestinal effect Effects 0.000 description 23
- 206010058858 Meningococcal bacteraemia Diseases 0.000 description 22
- 208000022089 meningococcemia Diseases 0.000 description 22
- 241000700199 Cavia porcellus Species 0.000 description 21
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- 230000004044 response Effects 0.000 description 20
- 239000000427 antigen Substances 0.000 description 18
- 108091007433 antigens Proteins 0.000 description 18
- 102000036639 antigens Human genes 0.000 description 18
- 108010076504 Protein Sorting Signals Proteins 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 210000002768 hair cell Anatomy 0.000 description 17
- 239000007788 liquid Substances 0.000 description 17
- 230000001939 inductive effect Effects 0.000 description 16
- 230000008521 reorganization Effects 0.000 description 16
- 210000001331 nose Anatomy 0.000 description 15
- 230000008569 process Effects 0.000 description 14
- 229910017119 AlPO Inorganic materials 0.000 description 13
- 238000010241 blood sampling Methods 0.000 description 13
- 239000013592 cell lysate Substances 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 238000011160 research Methods 0.000 description 13
- 108091008146 restriction endonucleases Proteins 0.000 description 13
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 13
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 12
- 239000012980 RPMI-1640 medium Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 11
- 238000010276 construction Methods 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 229960002989 glutamic acid Drugs 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 241001493546 Suina Species 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 238000000502 dialysis Methods 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- HEGSGKPQLMEBJL-UHFFFAOYSA-N n-octyl beta-D-glucopyranoside Natural products CCCCCCCCOC1OC(CO)C(O)C(O)C1O HEGSGKPQLMEBJL-UHFFFAOYSA-N 0.000 description 10
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 9
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 238000006073 displacement reaction Methods 0.000 description 8
- 239000000975 dye Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 238000004321 preservation Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 238000005352 clarification Methods 0.000 description 7
- 238000013467 fragmentation Methods 0.000 description 7
- 238000006062 fragmentation reaction Methods 0.000 description 7
- 230000005847 immunogenicity Effects 0.000 description 7
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 239000012266 salt solution Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229920000136 polysorbate Polymers 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 238000007789 sealing Methods 0.000 description 6
- 238000007920 subcutaneous administration Methods 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 206010008342 Cervix carcinoma Diseases 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- AQLHORCVPGXDJW-IUCAKERBSA-N Gly-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)CN AQLHORCVPGXDJW-IUCAKERBSA-N 0.000 description 5
- CQQGCWPXDHTTNF-GUBZILKMSA-N Leu-Ala-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O CQQGCWPXDHTTNF-GUBZILKMSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241001460678 Napo <wasp> Species 0.000 description 5
- HBZBPFLJNDXRAY-FXQIFTODSA-N Ser-Ala-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O HBZBPFLJNDXRAY-FXQIFTODSA-N 0.000 description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 244000309466 calf Species 0.000 description 5
- 201000010881 cervical cancer Diseases 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 5
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 4
- BHFOJPDOQPWJRN-XDTLVQLUSA-N Ala-Tyr-Gln Chemical compound C[C@H](N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(N)=O)C(O)=O BHFOJPDOQPWJRN-XDTLVQLUSA-N 0.000 description 4
- GXCSUJQOECMKPV-CIUDSAMLSA-N Arg-Ala-Gln Chemical compound C[C@H](NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O GXCSUJQOECMKPV-CIUDSAMLSA-N 0.000 description 4
- BPAUXFVCSYQDQX-JRQIVUDYSA-N Asp-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC(=O)O)N)O BPAUXFVCSYQDQX-JRQIVUDYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- CVFOYJJOZYYEPE-KBPBESRZSA-N Gly-Lys-Tyr Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CVFOYJJOZYYEPE-KBPBESRZSA-N 0.000 description 4
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 206010018612 Gonorrhoea Diseases 0.000 description 4
- QICVAHODWHIWIS-HTFCKZLJSA-N Ile-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N QICVAHODWHIWIS-HTFCKZLJSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 241000880493 Leptailurus serval Species 0.000 description 4
- HGFGEMSVBMCFKK-MNXVOIDGSA-N Leu-Ile-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(O)=O HGFGEMSVBMCFKK-MNXVOIDGSA-N 0.000 description 4
- AUNMOHYWTAPQLA-XUXIUFHCSA-N Leu-Met-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AUNMOHYWTAPQLA-XUXIUFHCSA-N 0.000 description 4
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 4
- 108010001267 Protein Subunits Proteins 0.000 description 4
- 102000002067 Protein Subunits Human genes 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- KNZQGAUEYZJUSQ-ZLUOBGJFSA-N Ser-Asp-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N KNZQGAUEYZJUSQ-ZLUOBGJFSA-N 0.000 description 4
- BUWIKRJTARQGNZ-IHPCNDPISA-N Trp-Phe-Cys Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N BUWIKRJTARQGNZ-IHPCNDPISA-N 0.000 description 4
- PMDOQZFYGWZSTK-LSJOCFKGSA-N Val-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C PMDOQZFYGWZSTK-LSJOCFKGSA-N 0.000 description 4
- KLOHDWPABZXLGI-YWUHCJSESA-M ampicillin sodium Chemical compound [Na+].C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C([O-])=O)(C)C)=CC=CC=C1 KLOHDWPABZXLGI-YWUHCJSESA-M 0.000 description 4
- 230000027645 antigenic variation Effects 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 108010016616 cysteinylglycine Proteins 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 108010049041 glutamylalanine Proteins 0.000 description 4
- 108010037850 glycylvaline Proteins 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000005304 joining Methods 0.000 description 4
- 108010064235 lysylglycine Proteins 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229930182817 methionine Natural products 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 108010003137 tyrosyltyrosine Proteins 0.000 description 4
- AMGQTNHANMRPOE-LKXGYXEUSA-N Asn-Thr-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O AMGQTNHANMRPOE-LKXGYXEUSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 3
- MCNGIXXCMJAURZ-VEVYYDQMSA-N Met-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)N)O MCNGIXXCMJAURZ-VEVYYDQMSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
- 241000190932 Rhodopseudomonas Species 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- LKEKWDJCJSPXNI-IRIUXVKKSA-N Thr-Glu-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LKEKWDJCJSPXNI-IRIUXVKKSA-N 0.000 description 3
- MVFQLSPDMMFCMW-KKUMJFAQSA-N Tyr-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O MVFQLSPDMMFCMW-KKUMJFAQSA-N 0.000 description 3
- 230000002303 anti-venom Effects 0.000 description 3
- 230000010065 bacterial adhesion Effects 0.000 description 3
- 230000008436 biogenesis Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 229940059082 douche Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 210000001989 nasopharynx Anatomy 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 101150079601 recA gene Proteins 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CVGNCMIULZNYES-WHFBIAKZSA-N Ala-Asn-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O CVGNCMIULZNYES-WHFBIAKZSA-N 0.000 description 2
- GSCLWXDNIMNIJE-ZLUOBGJFSA-N Ala-Asp-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GSCLWXDNIMNIJE-ZLUOBGJFSA-N 0.000 description 2
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 2
- NHLAEBFGWPXFGI-WHFBIAKZSA-N Ala-Gly-Asn Chemical compound C[C@@H](C(=O)NCC(=O)N[C@@H](CC(=O)N)C(=O)O)N NHLAEBFGWPXFGI-WHFBIAKZSA-N 0.000 description 2
- SMCGQGDVTPFXKB-XPUUQOCRSA-N Ala-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N SMCGQGDVTPFXKB-XPUUQOCRSA-N 0.000 description 2
- TZDNWXDLYFIFPT-BJDJZHNGSA-N Ala-Ile-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O TZDNWXDLYFIFPT-BJDJZHNGSA-N 0.000 description 2
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 description 2
- LDLSENBXQNDTPB-DCAQKATOSA-N Ala-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LDLSENBXQNDTPB-DCAQKATOSA-N 0.000 description 2
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 2
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 2
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 2
- ISCYZXFOCXWUJU-KZVJFYERSA-N Ala-Thr-Met Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(O)=O ISCYZXFOCXWUJU-KZVJFYERSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- RWCLSUOSKWTXLA-FXQIFTODSA-N Arg-Asp-Ala Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RWCLSUOSKWTXLA-FXQIFTODSA-N 0.000 description 2
- PBSQFBAJKPLRJY-BYULHYEWSA-N Asn-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N PBSQFBAJKPLRJY-BYULHYEWSA-N 0.000 description 2
- SNYCNNPOFYBCEK-ZLUOBGJFSA-N Asn-Ser-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O SNYCNNPOFYBCEK-ZLUOBGJFSA-N 0.000 description 2
- MJIJBEYEHBKTIM-BYULHYEWSA-N Asn-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N MJIJBEYEHBKTIM-BYULHYEWSA-N 0.000 description 2
- VPPXTHJNTYDNFJ-CIUDSAMLSA-N Asp-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N VPPXTHJNTYDNFJ-CIUDSAMLSA-N 0.000 description 2
- GCACQYDBDHRVGE-LKXGYXEUSA-N Asp-Thr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC(O)=O GCACQYDBDHRVGE-LKXGYXEUSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241001478240 Coccus Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 230000007023 DNA restriction-modification system Effects 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 229920004934 Dacron® Polymers 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQWMZOIPXWSZNE-WDSKDSINSA-N Gln-Asp-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O WQWMZOIPXWSZNE-WDSKDSINSA-N 0.000 description 2
- YPFFHGRJCUBXPX-NHCYSSNCSA-N Gln-Pro-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O)C(O)=O YPFFHGRJCUBXPX-NHCYSSNCSA-N 0.000 description 2
- RLZBLVSJDFHDBL-KBIXCLLPSA-N Glu-Ala-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RLZBLVSJDFHDBL-KBIXCLLPSA-N 0.000 description 2
- WVYJNPCWJYBHJG-YVNDNENWSA-N Glu-Ile-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O WVYJNPCWJYBHJG-YVNDNENWSA-N 0.000 description 2
- DTLLNDVORUEOTM-WDCWCFNPSA-N Glu-Thr-Lys Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O DTLLNDVORUEOTM-WDCWCFNPSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 2
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 2
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 2
- FXGRXIATVXUAHO-WEDXCCLWSA-N Gly-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN FXGRXIATVXUAHO-WEDXCCLWSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- RVKIPWVMZANZLI-UHFFFAOYSA-N H-Lys-Trp-OH Natural products C1=CC=C2C(CC(NC(=O)C(N)CCCCN)C(O)=O)=CNC2=C1 RVKIPWVMZANZLI-UHFFFAOYSA-N 0.000 description 2
- HAPWZEVRQYGLSG-IUCAKERBSA-N His-Gly-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O HAPWZEVRQYGLSG-IUCAKERBSA-N 0.000 description 2
- SKOKHBGDXGTDDP-MELADBBJSA-N His-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CN=CN2)N SKOKHBGDXGTDDP-MELADBBJSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- NCSIQAFSIPHVAN-IUKAMOBKSA-N Ile-Asn-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N NCSIQAFSIPHVAN-IUKAMOBKSA-N 0.000 description 2
- LKACSKJPTFSBHR-MNXVOIDGSA-N Ile-Gln-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N LKACSKJPTFSBHR-MNXVOIDGSA-N 0.000 description 2
- JXMSHKFPDIUYGS-SIUGBPQLSA-N Ile-Glu-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N JXMSHKFPDIUYGS-SIUGBPQLSA-N 0.000 description 2
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 2
- WGCKDDHUFPQSMZ-ZPFDUUQYSA-N Lys-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN WGCKDDHUFPQSMZ-ZPFDUUQYSA-N 0.000 description 2
- OWRUUFUVXFREBD-KKUMJFAQSA-N Lys-His-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O OWRUUFUVXFREBD-KKUMJFAQSA-N 0.000 description 2
- UYAKZHGIPRCGPF-CIUDSAMLSA-N Met-Glu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)N UYAKZHGIPRCGPF-CIUDSAMLSA-N 0.000 description 2
- RMLLCGYYVZKKRT-CIUDSAMLSA-N Met-Ser-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O RMLLCGYYVZKKRT-CIUDSAMLSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- UUHXBJHVTVGSKM-BQBZGAKWSA-N Pro-Gly-Asn Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UUHXBJHVTVGSKM-BQBZGAKWSA-N 0.000 description 2
- KWMZPPWYBVZIER-XGEHTFHBSA-N Pro-Ser-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KWMZPPWYBVZIER-XGEHTFHBSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 2
- ZOPISOXXPQNOCO-SVSWQMSJSA-N Ser-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)N ZOPISOXXPQNOCO-SVSWQMSJSA-N 0.000 description 2
- GVIGVIOEYBOTCB-XIRDDKMYSA-N Ser-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC(C)C)C(O)=O)=CNC2=C1 GVIGVIOEYBOTCB-XIRDDKMYSA-N 0.000 description 2
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 2
- FLMYSKVSDVHLEW-SVSWQMSJSA-N Ser-Thr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLMYSKVSDVHLEW-SVSWQMSJSA-N 0.000 description 2
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 2
- WFUAUEQXPVNAEF-ZJDVBMNYSA-N Thr-Arg-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)O)C(O)=O)CCCN=C(N)N WFUAUEQXPVNAEF-ZJDVBMNYSA-N 0.000 description 2
- NRUPKQSXTJNQGD-XGEHTFHBSA-N Thr-Cys-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NRUPKQSXTJNQGD-XGEHTFHBSA-N 0.000 description 2
- XNTVWRJTUIOGQO-RHYQMDGZSA-N Thr-Met-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O XNTVWRJTUIOGQO-RHYQMDGZSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- GQVZBMROTPEPIF-SRVKXCTJSA-N Tyr-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GQVZBMROTPEPIF-SRVKXCTJSA-N 0.000 description 2
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 description 2
- OGNMURQZFMHFFD-NHCYSSNCSA-N Val-Asn-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N OGNMURQZFMHFFD-NHCYSSNCSA-N 0.000 description 2
- APQIVBCUIUDSMB-OSUNSFLBSA-N Val-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N APQIVBCUIUDSMB-OSUNSFLBSA-N 0.000 description 2
- KTEZUXISLQTDDQ-NHCYSSNCSA-N Val-Lys-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N KTEZUXISLQTDDQ-NHCYSSNCSA-N 0.000 description 2
- IJGPOONOTBNTFS-GVXVVHGQSA-N Val-Lys-Glu Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O IJGPOONOTBNTFS-GVXVVHGQSA-N 0.000 description 2
- VPGCVZRRBYOGCD-AVGNSLFASA-N Val-Lys-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O VPGCVZRRBYOGCD-AVGNSLFASA-N 0.000 description 2
- VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 description 2
- MNSSBIHFEUUXNW-RCWTZXSCSA-N Val-Thr-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N MNSSBIHFEUUXNW-RCWTZXSCSA-N 0.000 description 2
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010008355 arginyl-glutamine Proteins 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000019365 chlortetracycline Nutrition 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000001332 colony forming effect Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 108010045383 histidyl-glycyl-glutamic acid Proteins 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- MVFCKEFYUDZOCX-UHFFFAOYSA-N iron(2+);dinitrate Chemical compound [Fe+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MVFCKEFYUDZOCX-UHFFFAOYSA-N 0.000 description 2
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000016379 mucosal immune response Effects 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000015047 pilsener Nutrition 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 108010053725 prolylvaline Proteins 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 108010046845 tryptones Proteins 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- BMYCCWYAFNPAQC-UHFFFAOYSA-N 2-[dodecyl(methyl)azaniumyl]acetate Chemical group CCCCCCCCCCCCN(C)CC(O)=O BMYCCWYAFNPAQC-UHFFFAOYSA-N 0.000 description 1
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- XAEWTDMGFGHWFK-IMJSIDKUSA-N Ala-Asp Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC(O)=O XAEWTDMGFGHWFK-IMJSIDKUSA-N 0.000 description 1
- LMFXXZPPZDCPTA-ZKWXMUAHSA-N Ala-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N LMFXXZPPZDCPTA-ZKWXMUAHSA-N 0.000 description 1
- 241000272478 Aquila Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- MSBDSTRUMZFSEU-PEFMBERDSA-N Asn-Glu-Ile Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O MSBDSTRUMZFSEU-PEFMBERDSA-N 0.000 description 1
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 1
- VXLBDJWTONZHJN-YUMQZZPRSA-N Asn-His-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N VXLBDJWTONZHJN-YUMQZZPRSA-N 0.000 description 1
- YNQIDCRRTWGHJD-ZLUOBGJFSA-N Asp-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(O)=O YNQIDCRRTWGHJD-ZLUOBGJFSA-N 0.000 description 1
- QRULNKJGYQQZMW-ZLUOBGJFSA-N Asp-Asn-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O QRULNKJGYQQZMW-ZLUOBGJFSA-N 0.000 description 1
- FRYULLIZUDQONW-IMJSIDKUSA-N Asp-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(O)=O FRYULLIZUDQONW-IMJSIDKUSA-N 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- UHVIQGKBMXEVGN-WDSKDSINSA-N Glu-Gly-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UHVIQGKBMXEVGN-WDSKDSINSA-N 0.000 description 1
- WRNAXCVRSBBKGS-BQBZGAKWSA-N Glu-Gly-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O WRNAXCVRSBBKGS-BQBZGAKWSA-N 0.000 description 1
- XTZDZAXYPDISRR-MNXVOIDGSA-N Glu-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N XTZDZAXYPDISRR-MNXVOIDGSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SWQALSGKVLYKDT-ZKWXMUAHSA-N Gly-Ile-Ala Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O SWQALSGKVLYKDT-ZKWXMUAHSA-N 0.000 description 1
- LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- NQKRILCJYCASDV-QWRGUYRKSA-N His-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 NQKRILCJYCASDV-QWRGUYRKSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 241001454354 Kingella Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 241001484259 Lacuna Species 0.000 description 1
- TZSUCEBCSBUMDP-SRVKXCTJSA-N Leu-Leu-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O TZSUCEBCSBUMDP-SRVKXCTJSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- YFGWNAROEYWGNL-GUBZILKMSA-N Lys-Gln-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YFGWNAROEYWGNL-GUBZILKMSA-N 0.000 description 1
- HKXSZKJMDBHOTG-CIUDSAMLSA-N Lys-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN HKXSZKJMDBHOTG-CIUDSAMLSA-N 0.000 description 1
- 206010027249 Meningitis meningococcal Diseases 0.000 description 1
- 201000010924 Meningococcal meningitis Diseases 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 229940124912 Neisseria meningitidis vaccine Drugs 0.000 description 1
- 241001212279 Neisseriales Species 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 241000845082 Panama Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- FUVBEZJCRMHWEM-FXQIFTODSA-N Pro-Asn-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O FUVBEZJCRMHWEM-FXQIFTODSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- HZDQUVQEVVYDDA-ACRUOGEOSA-N Tyr-Tyr-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HZDQUVQEVVYDDA-ACRUOGEOSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- UVHFONIHVHLDDQ-IFFSRLJSSA-N Val-Thr-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O UVHFONIHVHLDDQ-IFFSRLJSSA-N 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000024754 bloodshot eye Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229950001485 cocarboxylase Drugs 0.000 description 1
- 229960001127 colistin sulfate Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000013010 irrigating solution Substances 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000001698 laser desorption ionisation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- ZESIAEVDVPWEKB-ORCFLVBFSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O ZESIAEVDVPWEKB-ORCFLVBFSA-N 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000009400 out breeding Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- RVZHUQPIBHMAEX-UHFFFAOYSA-N sodium;isocyanate Chemical compound [Na+].[N-]=C=O RVZHUQPIBHMAEX-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The pilE genes of neisseria gonorrhoeae and neisseria meningitidis are cloned separately and their corresponding recombinant pilin proteins are expressed. In addition, a chimeric pilE gene was constructed in which the region of the pilE gene from Neisseria meningitidis class I which encodes the amino-terminal region of the pilin protein was replaced by the corresponding region of the pilE gene from Neisseria gonorrhoeae. The recombinant meningococcal class I pilin protein is expressed at a level higher than that expressed by the full-length pilE gene of Neisseria meningitidis. In addition, a chimeric pilE gene was constructed in which the region of the pilE from Neisseria meningitidis class II encoding the carboxy-terminal region of the pilin protein was replaced by the corresponding region of the pilE gene from Neisseria gonorrhoeae. The recombinant pilin proteins are useful in vaccines to protect against disease caused by Neisseria gonorrhoeae or Neisseria meningitidis.
Description
Invention field
The present invention relates to the disease that the employing recombinant pilin protects body prevention Diplococcus gonorrhoeae (Neisseria gonorrhoeae) or Neisseria meningitidis (Neisseria meningitidis) to cause in vaccine.
Background of invention
Diplococcus gonorrhoeae (N.gonorrhoeae) and Neisseria meningitidis (N.meningitidis) are Gram-negative coccus.Very close on Diplococcus gonorrhoeae and the Neisseria meningitidis gene, but difference is very big in the clinical manifestation of their associated diseases.Diplococcus gonorrhoeae is caused gonorrhoea, and Neisseria meningitidis causes meningococcal meningitis.These Neisserial bacteriums are present in the mucomembranous surface of body.
IV type pili is the non-flagellum hair shape structure on many gram negative bacteriums surface, these gram negative bacteriums comprise: the plethora artiodactyl shape bacterium of artiodactyl shape Pseudomonas (Bacteroides originally), erode the Aitken bacterium, denitrification (denitrogenation) Kingella, ox catarrhalis, lacuna catarrhalis, catarrhalis does not liquefy, Diplococcus gonorrhoeae, Neisseria meningitidis and Pseudomonas aeruginosa (Bibliography Entries 1,2).The bundle that the toxin of vibrio cholerae is regulated pili and enteropathogenic Escherichia coli altogether forms pili and shows similarity with IV type pili limited quantity, it is believed that it is remote relationship (1,2).For gonococcus and meningococcus, fimbriate bacterium is more much higher in various HE avidity than the bacterial adhesion of no pili, so think that pili is that the microorganism anchor in the virulence factor at mucosal infections position.
IV type pili is wide to be 5-7nM, and length is 5 μ M.The subunit of pilin is connected in series and forms long and thin polymer.For pathogenic eisseria, the pili outward appearance is natural homopolymer, forms pilin by the subunit of single structure.The molecular weight of pilin is 13,000-22,000 dalton (1,2,3).
The natural bacterial outer membrane that is assembled to of pilin is called in the spirane structure of pili, and the molecular weight of this adventitia is about 10
7Dalton.When the pili of purifying was dialysed with the phosphoric acid buffer of pH12, the irreversible pilin condensation product that resolves into of complete pili was called pilin oligomer (4).The size of the condensation product of these pili oligomer (molecular weight is about 600,000 dalton) is more much smaller than complete pili.
The single pilin that Diplococcus gonorrhoeae is expressed is isolated by Schoolnik and its co-worker at first, and order-checking (5).The gonococcus pilin is made up of following three zones: (a) the aminoterminal zone of highly protecting (residue 1-53); (b) this district of region intermediate (residue 54-124) show limited amount sequence variations and (c) proteic third part be carboxyl terminal (residue 125-160), contain two sulphur rings of alterable height.
In the natural infection process, pili experiences and resembles and antigenic variation (3,6) when high-frequency.The genetics of this variation is complicated especially, has carried out extensive studies.Every strain gonococcus all has the ability to change the one-level aminoacid sequence of pili molecule, thereby changes the antigenic property of its pili.The molecule mechanism of being responsible for this variation relates to: the non-interchangeability reorganization (6) between expressing gene seat (pilE) and numerous (17 to 19) non-promotor silences (pilS) gene.Pili sequence (or its part) moves to an expressing gene seat from the pilS locus, produces new pili variation, thereby makes gonococcus can express extremely a large amount of pilins.
Opposite with gonococcus, meningococcus is only expressed two kinds of different types of pili, is called I class and II class pili.The same with gonococcus, meningococcus I class pili experience antigenicity and the time elephant variation (3).It is similar to gonococcus pili molecular weight (17-20kd) that I class pili shows, with reactive similar (epi-position of highly protecting on this monoclonal antibody and the gonococcus pili combines) (3) of monoclonal antibody (SM1).Cloned many I class pili, the sequence of displaying acid sequence and gonococcus pili has high similarity (7).On the contrary, II class pili not with SM1 antibody response, and molecular weight also lower (13-16kd).Several bacterial strains of expressing II class pili show and can react with the polyclonal antiserum of anti-gonococcus pili.People such as Aho (7) have determined the sequence of II class pili recently.Trizonal first zone of Neisseria pili is identical basically.II class pilin has big disappearance to take place with the different hypervariable regions that are of I class pili and gonococcus pili.People such as Achtman (8) adopt the monoclonal antibody specific of I class or II class pili, have proved that some serogroups A isolates in Africa all combine with two kinds of antibody.Verified bacterial strain of expressing I class pili also amputation reticent I class pili gene (7).Combine and see, unicellular possibility of expressing two kinds of pilins simultaneously of meningococcus of these data promptings.
Contacting owing to thinking that pili has mediated with the initial of mucomembranous cell, is the disease of preventing the pili bacterium to cause as vaccine antigen these structures so be worth interested.In the crowd, carried out the test (9) of pili vaccine prevention traveler's diarrhea and gonorrhoea.Yet they are only effective to homologous strain so far.It is reported that some vaccines based on pili have been used for the disease that domestic animal suffers from, as IKB (blood-shot eye illness) (1), rot disease (1,10) and young pig (9) or calf (9) of poker suffered from diarrhoea.In the example of every kind of this class animal doctor research, the pili vaccine provides the protection of avoiding expressing homology rather than the attack of allos pili bacterial strain.
Gonococcus vaccine the earliest comprises whole microbe, seldom or not provides provide protection but provide.The exploitation of antigonococcique vaccine recently focuses on surface component, particularly pili (9,11) and the porin (P.I or Por) (11) of purifying.Yet so far, have only pili to demonstrate and can protect human body to be immune against attacks, and this be limited to the protection human body resist homologous strain (12).The denatured form (4) that has shown the gonococcus pili can produce in mouse and cavy can be at external antibody in conjunction with the allos pili.Yet, do not think that this is the method for viable commercial, because the gonococcus of the hair that carries disease germs in the liquid medium within (commercial production is essential) is difficult to growth (1).Based on the success of preliminary people's Attack Research, render a service the test (12) of having carried out gonococcus pili vaccine in the experiment an extensive placebo double blinding.In this experiment, this vaccine can not protect male volunteers to avoid gonococcal infection.Infer the most probable unhomogeneity (12) that is interpreted as pili of this situation.
Really the antigenic variation of gonococcus and meningococcal pilin is the major obstacle (3,13,14,15,16,17) to be enumerated repeatedly in the vaccine development of pili.Existing people proposes: the immunodominant epitope on the complete pili of assembling is two sulphur rings, and this ring presents maximum sequence variations (17,18).This has just explained the complete pili of the gonococcus bacterial strain Pgh3-2 that handles with formalin, in the reason (12) of Korea S's field experiment failure.In addition, some reference that this paper comprises are wherein referred to the pili of antivenom purification, or the segmental antiserum(antisera) of pilin, can be incorporated into sex change (Western trace) or isolating Neisseria hair, but not combine (16 with the allos pili of bacterium surface, 17,19,20).Also do not understand fully this whether be since in the pili of assembling the antigenic variation of epi-position or hidden due to.Some reports have been emphasized this point, and these report proofs are only in the external monoclonal antibody that presents functionally active, be only those not with allos pili bonded antibody (3).The complete pili of ox catarrhalis and plethora artiodactyl shape bacterium shows that it is possible (10) that pili causes protective immune response.Yet these vaccines can only protect the body opposing to express the attack (10,21) of the bacterium of homology pili rather than allos pili.Scientific circles are consistent to be thought and it seems vaccine based on pili, if possible, will only protect the body prevention to express the bacterium of homology pili.
The pili of recombinant expressed assembling is all described in many microbies, and it depends on suitable transhipment and assembled base because of (22).For Neisseria, do not find that in a continuous operon coding participates in the gene of pili assembling and translocator, so this method is infeasible.The another kind of alternative method of selecting in European patent 202,260 B1 is that (this host has had the required albumen of the different IV pili of assembling certain host bacterium; As Pseudomonas aeruginosa) the middle IV pili gene (23) of expressing.But report that as people such as Hoyne expressing and assemble the gonococcus pili is unsettled (24) on the Rhodopseudomonas adventitia.When growing in there is the liquid nutrient medium of selective antibiotic element in this kind recombinant bacterial strain, wild-type is carried disease germs the Rhodopseudomonas of hair can hypertrophy.The author is presented below:
" the consistency of external source mePhe in the host strain (N-methylbenzene L-Ala) pilin product
The divergent degree of host and donor pilin line system will be relied on.Ball is drenched in observed expression
The unstable of the PAK/2PfS of bacterium pilin (Pseudomonas aeruginosa K/2PfS strain) ... can
Can show and express the limited method used in this example that is between mePhe pili kind." (24) owing to this result, expression gonococcus pili can not be thought the method for viable commercial in Rhodopseudomonas.
Elleman, Egerton and co-worker have described the vaccine with the complete pili exploitation opposing poker canker of plethora artiodactyl shape bacterium.The plethora artiodactyl shape bacterium infection of expression homology pili that the complete pili of field experiment demonstration has been protected zooprophylazis.This means that commercially available vaccine must contain 8 or 9 kind of different pili, to realize all-round protection.In order to make this method feasible, cloned the pili gene of plethora artiodactyl shape bacterium, and in expression in escherichia coli (25).Find that recombinant pilin combines with inner membrance.When test contains intestinal bacteria (supersound process is crossed) cell vaccine of express recombinant pilin in challenge trial, the antibody titers that recombinant Bacillus coli cells produces and similar (25) of the natural pili of purifying.Yet the agglutination titer that the recombinant Bacillus coli cells vaccine produces is obviously lower than (690 couples of .47,800) of complete pili, and is lower than the relevant titre (5,000-10,000) (25,26) of protectiveness.
After doing active the attack with plethora artiodactyl shape bacterium, with shown opposite of complete pili, the recombinant pilin vaccine can not demonstrate any significant protection activity.Emery and its co-worker show that the sex change of complete pili abolished pili is induced protection in animal ability (27).In addition, recovered this proteic effectiveness (causing the formation that protection avoids attacking the serious pathology in back) (28) with stain remover (octyl-β-D-glucoside) or the dissociated pili of low pH (2.2).And no matter in fact not significantly difference of antibody titers between each group.The author states " having one or more epi-positions relevant with quaternary structure (being destroyed with processed) ".They further state:
" e. coli expression product is done the vaccine failure, may be because its thing on host cell membrane
Rational occlusion causes, though preliminary experiment shows that this is not to cause its invalid major cause (not have
Display data is arranged).The vaccine failure of another kind do to(for) e. coli expression product is interpreted as:
The pilin unit may be because the existence of leader sequence not can be incorporated into the sky before the unit of expressing
In the right conformation (suitably to present important epi-position).”(28)。
Elleman and its co-worker confirm to have the importance of conformational epitope on recombinant pilin, and confirm that they need increase immunne response by antigenic better presenting.They advise two kinds of methods: from this albumen of escherichia coli membrane purifying; Or in Pseudomonas aeruginosa, express this albumen, make in its fibril pili that can be assembled to cell surface.A kind of method in back is preferable, because " this will improve immunogenicity greatly and simplify proteic purifying " (25).
In addition, Elleman and its co-worker have also looked back employing pilin (protein subunit of pili) as the complete inferior candidate vaccine of the ripe fibril pili of plethora artiodactyl shape bacterium:
" it seems that ripe pili can cause stronger and suitable than the fibril pili protein subunit with dosage
The immune response of (that is K-aggegation).About 5,000 K-agglutination titer on serology
Be commonly considered as minimum and reply, certain given plethora artiodactyl shape bacteria strain sense is replied and resisted to this minimum
The enough protective immunities that dye are suitable.The level of replying like this (reaching the higher order of magnitude)
Realize by inoculating ripe pili vaccine easily, (can only draw but inoculate isolating protein subunit
Send out serum K-agglutinating antibody low-level) can not realize " (23).
People such as nearest Alves have reported additional data, the uncomfortable cooperation candidate vaccine (29) of prompting fibril pili protein subunit.When mouse immune has been inoculated the polynucleotide vaccine of coding intestinal bacteria CFA/I pili adhesin albumen (as pilin), induce the antibody of generation to induce the different of generation with natural complete CFA/I pili.In addition, the antibody of these anti-recombinant proteins is opposite with the antiserum(antisera) of anti-native protein, does not show any agglutination activity.
Except above-mentioned work, a kind of effective gonococcus or meningococcus vaccine have also been developed based on pili.Meningococcus vaccine is limited to those vaccines with serotype A, C, Y and W135 pod membrane.
Therefore, need evaluation to be used for protecting body to resist the component of the vaccine of the disease that causes by gonococcus or all serotypes of meningococcus.
Brief summary of the invention
Thus, an object of the present invention is to identify respectively that it may form the feasibility candidate vaccine of resisting these bacteriums by gonococcus and meningococcal derivatized suitable antigenicity structure.These candidate vaccines must be able to be induced, body identification and in conjunction with the antibody of the multiple isolate of each pathogenic Neisseria.
Following these and other objects of the present invention are by the clone and express gonococcus and meningococcal recombinant pilin (rpilin) is realized.
The invention still further relates to a kind of structure of plasmid, the I class pilin that this plasmid expression meningococcus is chimeric, wherein the aminoterminal zone of I parameningococcus pilin is by the corresponding aminoterminal regional replacement of gonococcus pilin.The amount of the meningococcus mosaic I class recombinant pilin of this plasmid expression is significantly higher than the amount of the I parameningococcus recombinant pilin of total length meningococcus pilE genetic expression.
In order to obtain the expression of the chimeric I class recombinant pilin of meningococcus, gomphosis DNA array at first is inserted in the suitable plasmid vector.Transform or appropriate host cell of transfection with this plasmid then.In one embodiment of this invention, host cell is a coli strain.Under the condition that makes the described chimeric I class recombinant pilin of host cell expression, cultivate this host cell then.
The invention still further relates to and make up a kind of plasmid, the II class pilin that this plasmid expression meningococcus is chimeric, wherein the carboxyl terminal zone of II parameningococcus pilin is by the corresponding carboxyl terminal regional replacement of gonococcus pilin.
In order to obtain the expression of the chimeric II class recombinant pilin of meningococcus, gomphosis DNA array at first is inserted in the suitable plasmid vector.Transform or appropriate host cell of transfection with this plasmid then.In one embodiment of this invention, host cell is a coli strain.Under the condition that makes the described chimeric II class recombinant pilin of host cell expression, cultivate this host cell then.
In another embodiment of the present invention, will separate and the recombinant pilin (gonococcus, meningococcus or chimeric) of purifying is used to prepare vaccine composition, said composition can cause protective immune response in mammalian hosts.This vaccine composition can further comprise adjuvant, diluent or carrier.The example of adjuvant comprises aluminium hydroxide, aluminum phosphate, MPL
TM, Srimulon
TM, QS-21, IL-12 and Toxins,exo-, cholera.Give mammalian hosts with this vaccine composition with enough immunogenicity amounts, resist the disease that gonococcus or meningococcus are caused with the protection host.
Brief Description Of Drawings
Fig. 1 has described the hair cell that carries disease germs of gonococcus (bacterial strain I756 recA-) under the transmission electron microscope, after the anti-gonococcus recombinant pilin of cavy (obtaining) antiserum(antisera) (dilution in 1: 50 15 minutes) cultivation from bacterial strain Pgh3-1, with (the dilution in 1: 5 of the anti-cavy IgG of donkey link coupled 12nm Radioactive colloidal gold, 30 minutes) reaction, dye with NanoVan again.Figure 1A is an anti-recombinant pilin cavy immune serum (the 6th week); Figure 1B is normal guinea pig serum (the 0th week); Fig. 1 C does not have first antibody (primary antibody).
Fig. 2 has described the anti-gonococcus recombinant pilin of cavy (obtaining from bacterial strain Pgh3-1) antiserum(antisera), the gonococcus cell (bacterial strain I756 recA-) of the hair that carries disease germs is adhered to the effect of human cervical cancer 1 cell (ME180 clone).Fig. 2 A has described the anti-gonococcus recombinant pilin of cavy antiserum(antisera) to this inhibition of adhering to (the 6th week); Fig. 2 B has described normal guinea pig antiserum(antisera) can not prevent from the to carry disease germs gonococcus cell attachment cervical cell (the 0th week) of hair.Irised out the size that the representativeness that is incorporated into the bacterium of cervical cell in every group of experiment is gathered together.Every group of experiment shown following four the different visuals field of same experiment condition.Every group of experimental guinea pig antiserum(antisera) done 1: 10,000 dilution.
Fig. 3 has described the hair cell that carries disease germs of meningococcus (bacterial strain H355) under the transmission electron microscope, after I class recombinant pilin (obtaining from the bacterial strain H44/76) antiserum(antisera) chimeric with the cavy meningococcemia (dilution in 1: 60 30 minutes) cultivated, be coupled to (the dilution in 1: 5 of 12nm Radioactive colloidal gold with the anti-cavy IgG of donkey, 30 minutes) reaction, dye with NanoVan again.Fig. 3 A is an anti-recombinant pilin cavy immune serum (the 6th week); Fig. 3 B is normal guinea pig serum (the 0th week); Fig. 3 C does not have first antibody.Cell and antiserum(antisera) are fixing before cultivating.
Invention is described in detail
The present invention relates to contain the vaccine composition of gonococcus or meningococcus recombinant pilin. , although the above has discussed many, still determine the purposes of this recombinant pilin of research expression in escherichia coli. Surprisingly, these recombinant pilins demonstrate the feature of candidate vaccine.
First report that is described in clone gonococcus pilE gene in Escherichia coli is nineteen eighty-two (30). From then on, minute subcharacter of pilE has been carried out a large amount of following genic laboratory researches, these genes are being controlled the expression of pilin, the transhipment of pilin, the variation of pilin sequence and the host of pili and are being sticked together characteristic. Yet the neither one report has been described purifying or the restructuring of recombinant pilin and has been expressed the immune response of pilin.
Following embodiment 2 has described clone and the expression of the pilE gene of coding gonococcus recombinant pilin. Expression realizes by the Escherichia coli bacterial strain that use contains the Plasmid Transformation called after TOP10F ' of pilE gene. After successful clone and expression, by the order-checking confirmation of pilE gene and the homogeny of natural sequence. , in order to help the clone, introduced NcoI2 site (requiring to modify a base). As a result, the second amino acid in the long signal peptide of seven amino acid becomes aspartic acid from asparagine.
The plasmid (called after pPX2000) that contains the pilE gene in embodiment 2 includes an amicillin resistance (AmpR) mark. As described in example 3 above, build another and contained kanamycins resistance (KanR) mark, rather than AmpRPlasmid. This plasmid called after pPX2002, after it transforms Escherichia coli TOP10F ' bacterial strain, expressed the gonococcus recombinant pilin, and level is similar to pPX2000 and (contains AmpRMark) resulting level.
As described in Example 4, with similar scheme constructs called after pPX2003 contain a plasmid of meningococcus I class pili gene. Introduce NcoI site (CC ATG G), cross over the initiating terminal of code signal peptide gene. This becomes aspartic acid (the first residue still is methionine) with signal peptide the second amino acid residue from asparagine. Also comprise an AmpRMark. After this construction is transformed Escherichia coli TOP10F ' bacterial strain, expressed meningococcus I class recombinant pilin. Yet, the gonococcus recombinant pilin that the level of its expression significantly obtains lower than pPX2000 or pPX2002. Not bound by theory, this lower expression may be due to due to a large amount of inverted repeats (coming across in restructuring I class pilE).
, in order to increase the expression of meningococcus pilin, as described in Example 5, built a chimeric plasmid. Front 60 amino acid of the coding meningococcus I class recombinant pilin corresponding regional replacement of gonococcus DNA in pPX2002 in pPX2003. Resultant AmpRPlasmid called after pPX2004, its nucleotide sequence that has is seen SEQ ID NO:1. E. coli k12 strain with pPX2004 Plasmid Transformation called after TOP10F '. After inducing, the amount of the meningococcus recombinant pilin of expressing with pPX2003 is compared, and the chimeric recombinant pilin of expression has had remarkable increase. The amount of the gonococcus recombinant pilin that the expression of this chimeric construction and pPX2002 express is suitable. Chimeric I class recombinant pilin 167 amino acid of length (comprising burst) (SEQ ID NO:2), conform to the size of estimating.
The e. coli k12 strain of called after TOP10F ' (containing recombinant plasmid pPX2004), be deposited in the culture collection center by U.S. typical case on January 27th, 1998 by the applicant, 10801 University Boulevard, Manassas, Virginia 20110-2209, U.S.A., and specifying the ATCC accession number is ATCC98637.
As described in embodiment 6, the chimeric plasmid of structure, 3 ' end of its meningococcus II class pilE gene is replaced by gonococcal respective regions.Specifically, the DNA of coding two sulphur rings (last 22 amino acid of the meningococcus II class pilin of meningococcus bacterial strain FAM18) is added that by similar (but bigger) zone of gonococcus (pilE) DNA of gonococcus bacterial strain Pgh3-1 among the pPX2000 extention (amount to 44 amino acid) in carboxyl terminal zone replaces among the pPX8001.The Amp that the result obtains
RPlasmid called after pPX8017, the nucleotide sequence that it has see SEQ ID NO:3, and wherein Nucleotide 1-378 is from meningococcus II class, and Nucleotide 379-510 is from gonococcus.Transform the e. coli k12 strain of name TOP10F ' with plasmid pPX8017.After inducing, expressed chimeric II class recombinant pilin, its length is 170 amino acid (signal sequence that comprises 7 amino acid longs) (SEQ ID NO:4), and wherein amino acid/11-126 is from meningococcus II class, and amino acid/11 27-170 is from gonococcus.This chimeric II class recombinant pilin conforms to the size of expectation.Consider for the clone, a NcoI site is introduced, so second amino acid in the signal sequence is become L-glutamic acid from Methionin.Estimate that this variation can not have any influence to antigenicity or immunogenicity.
Carry the sample of the e. coli k12 strain (being called TOP10F ') of recombinant plasmid pPX8017, be preserved in American type culture collection (ATCC) (10801University Boulevard on April 15th, 1999 by the applicant, Manassas, Virginia 20110-2209, U.S.A.), its ATCC accession number is ATCC 207199.
Host cell one carrier system of describing in detail in embodiment 2-6, various host cell one carrier system all is suitable for expressing gonococcus used in the vaccine of the present invention, meningococcus and chimeric recombinant pilin.Carrier system should be compatible with used host cell.The host cell that is fit to comprises: with plasmid DNA, cosmid DNA or the bacterium of having a liking for the thallus DNA conversion; Virus is as vaccinia virus and adenovirus; Yeast such as Pichia cell; Insect cell such as Sf9 or Sf21 cell; Or mammal cell line such as Chinese hamster ovary cell; And other conventional organism.
Various routine is transcribed and is translated element and can be used for the host cell carrier system.PilE DNA is inserted an expression system, and promotor and other controlling elements are connected to the specific site of this carrier, when this plasmid vector was inserted into host cell, host cell can be expressed pilE DNA like this.
According to used host cell carrier system, can or infect plasmid is introduced host cell by conversion, transduction, transfection.Then, but under the condition of host cell express recombinant pilin, cultivate host cell.
The invention still further relates to the dna sequence dna of a kind of separation and purifying, the I class recombinant pilin that the dna sequence encoding meningococcus that it comprises is chimeric, this proteic aminoterminal zone from gonococcus pilE gene and its central authorities and the carboxyl terminal zone from meningococcus pilE gene (SEQ ID NO:1).The chimeric I class recombinant pilin of meningococcus before the Nucleotide 1-501 coding processing among the SEQ ID NO:1; Become the chimeric I class recombinant pilin of meningococcus of maturation protein after the processing of Nucleotide 22-501 coding.The invention still further relates to the chimeric I class recombinant pilin of meningococcus, this albumen has the aminoacid sequence (becoming maturation protein after the processing) of amino acid 8-167 among the aminoacid sequence (processing before) of amino acid/11-167 among the SEQ ID NO:2 or the SEQ ID NO:2.About 10% lacks signal sequence in the total protein that is produced by the chimeric I class recombinant pilin construction of gonococcus recombinant pilin or meningococcus, and it is removed by processing.
The invention still further relates to the dna sequence dna of a kind of separation and purifying, the II class recombinant pilin that the dna sequence encoding meningococcus that it comprises is chimeric, this proteic carboxyl terminal zone from gonococcus pilE gene and its central authorities and the aminoterminal zone from meningococcus pilE gene (SEQ ID NO:3).The II class recombinant pilin (before the processing) that Nucleotide 1-510 coding meningococcus among the SEQ ID NO:3 is chimeric; The chimeric II class recombinant pilin (becoming maturation protein after the processing) of Nucleotide 22-510 coding meningococcus.The present invention also relates to the chimeric II class recombinant pilin of meningococcus in addition, and this albumen has the aminoacid sequence (becoming maturation protein after the processing) of amino acid 8-170 among the aminoacid sequence (processing before) of amino acid/11-170 among the SEQ ID NO:4 or the SEQ ID NO:4.
The gomphosis DNA array in being included in pPX2004 and pPX8017 (the II class recombinant pilin that I class recombinant pilin that the meningococcus of encoding respectively is chimeric and meningococcus are chimeric), the present invention comprises that also (because genetic code Feng Yuxing) biologically is being equivalent to the dna sequence dna of the chimeric recombinant pilin of coding, that is to say, the feature of these other dna sequence dna, though it is different with nucleotide sequence shown in this article that it is a nucleotide sequence, coded identical of their coded proteinic aminoacid sequences and the dna sequence dna among SEQID NO:1 or the SEQID NO:2.
Specifically, the sequence that the present invention includes those and SEQ ID NO:1 or SEQ ID NO:3 has enough homogenies, thus the dna sequence dna that can hybridize down in highly rigorous Southern hybridization conditions (for example condition described in the people (31) such as Sambrook).
The present invention also comprises such dna sequence dna: its amino acid sequence coded is different from the recombinant pilin of chimeric I class of meningococcus or II class, but biologically is being equivalent to the aminoacid sequence (SEQ ID NO:2 or SEQ ID NO:4) of one of these albumen.These aminoacid sequences can be described as with those sequences of chimeric recombinant pilin of equal value biologically, if the difference of their sequences is small disappearance, the insertion of recombinant pilin sequence or substitutes, thereby make three grades of conformations of this sequence compare basically not variation with three grades of conformations of recombinant pilin.
For example, the residue (as glycine) that another hydrophobicity of codon available code of amino acid alanine (a kind of hydrophobic amino acid) is relatively poor, or the codon of the stronger residue (as Xie Ansuan, leucine or Isoleucine) of hydrophobicity substitutes.Similarly, change can be to cause a kind of electronegative residue alternative another (substituting L-glutamic acid as aspartic acid) or a kind of positively charged residue to substitute another (as Methionin place of arginine) and with substituting between the proximate residue of wetting ability, also can expect to produce biologically suitable product.The Nucleotide that expectation causes protein molecular N-end or C-end to change changes, but can not change activity of proteins.
In addition, the variation in known Variable Area is biologically of equal value, and wherein three of conserved regions grades of conformations do not change (with comparing of those recombinant pilins) basically.Biologically the another kind of equivalent sequence is defined as: the sequence of the immunne response of the generation cross reaction of still having the ability.Specifically, I class that meningococcus is chimeric and II recombinant pilin can be by the corresponding inset lengthening or the shortening of gonococcus pilin are modified, as long as the chimeric recombinant pilin of modifying still has the ability that produces the cross reaction immunne response.
The modification of each suggestion all is to adopt the ordinary skill in the art, whether has kept structure and biological activity as measuring coded product.So, used term " the I class recombinant pilin that meningococcus is chimeric " or " the II class recombinant pilin that meningococcus is chimeric " in specification sheets or claims is appreciated that this term has comprised and causes producing proteic all these modifications biologically of equal value and variation.
As described in embodiment 7, the gonococcus recombinant pilin combines with this proteic colibacillary cytolemma of expression.Multiple stain remover can the colibacillary recombinant pilin of selective dissolution, comprises Empigen
TMBB, Triton
TMX-100, reductive Triton
TMX-100, octyl-β-D-glucopyranoside (OG), Zwittergent
TM3-10 or 3-14.After centrifugal, the dialysis and use the post fractional separation, obtain the recombinant pilin of purifying.
As described in embodiment 8, chimeric I class recombinant pilin separates and purifying by the Bacillus coli cells that breaks, and by centrifugal clarification, filters, and separates at two column fractionations.
As described in embodiment 9, the chimeric II class recombinant pilin of meningococcus can separate and purifying by the Bacillus coli cells that breaks, by centrifugal clarification, and dialysis, and two column fractionations separation.
As described in embodiment 10, the gonococcus recombinant pilin of purifying is carried out the order-checking of multiple N-end.The consensus amino acid sequence that result that the order-checking of 20-40 aminoterminal residue provides and dna sequence dna are derived.The molecular weight that mass spectroscopy records recombinant pilin (signal sequence is arranged) is 18,006 dalton, meets very much quality 17,981 dalton (estimating according to aminoacid component) of expectation.On the contrary, when recombinant pilin carried out the size exclusion column chromatography with stain remover, the apparent molecular weight that obtains was 68,899 dalton.This prompting recombinant pilin aggegation.With the PBS recombinant pilin of dialysing, remove stain remover, the apparent molecular weight of gained material is 452,349 dalton (measuring with gel-filtration) as a result.This points out it to experience further aggegation.
As described in embodiment 11, with the gonococcus recombinant pilin immune guinea pig or the mouse acquisition immune serum of purifying.As listing among the embodiment 12, the Western engram analysis shows that the antiserum(antisera) of anti-recombinant pilin is incorporated into the full cell lysate of the gonococcus cell system of the hair that carries disease germs, and does not combine with the cell lysate of no pili.On the contrary, the antiserum(antisera) of antibiotic hairless protein oligomer be incorporated into the hair that carries disease germs with the cell lysate of no pili.
Describe in detail as embodiment 13, when using elisa assay, the antiserum(antisera) of the anti-gonococcus recombinant pilin of this blended has very high terminal point titre to the gonococcus recombinant pilin that is incorporated into purifying.Embodiment 13 also describes the effect of various adjuvants in detail.As recombinant pilin list MPL
TM, MPL
TMWith aluminum phosphate or Stimulon
TMWhen QS-21 makes adjuvant, in mouse, obtain good humoral immunoresponse(HI).
As listing among the embodiment 14, full cell ELISA shows that the antiserum(antisera) of anti-recombinant pilin is incorporated into the fimbriate cell of specific gonococcus bacterial strain, but debond does not have the cell of pili in homogenic specific gonococcus bacterial strain.
As described in embodiment 15, mouse is carried out immunization in the nose with gonococcus recombinant pilin (have or do not have natural Toxins,exo-, cholera).Mouse is with after the recombinant pilin immunization of no adjuvant, and the antigen ELISA of the pooled serum of generation has recorded significant immunne response; This replying owing to adding natural Toxins,exo-, cholera increases.Pooled serum is to very low in conjunction with complete fimbriate gonococcus cell ELISA titre; When mouse during with natural Toxins,exo-, cholera immunization, this combination improves greatly.
As described in embodiment 16, immuno-electron microscope shows pili fibril length (direction) combination of the antibody of anti-recombinant pilin along the gonococcus surface.This prompting internal antibody is incorporated into the epi-position that bacterium surface exists.
Embodiment 17 shows, compares with the result of reorganization pili oligomer antiserum(antisera) gained, and is higher with the allos capillary bacterium isolate bonded recombinant pilin antiserum(antisera) titre of carrying disease germs.With pH12 phosphoric acid buffer dialysis recombinant pilin, make recombinant pilin be transformed into the recombinant pilin oligomer.
Pili has mediated gonococcus and has combined with the preliminary of people's mucomembranous cell.So, if having the ability to cause, a kind of antigen stop gonococcus to be adsorbed in the antibody of people's mucomembranous cell, just proved that this antigen is candidate vaccine.
As described in example 18 above, the anti-recombinant pilin antiserum(antisera) of the cavy gonococcus that suppressed the expressing heterologous pili significantly combines with human cervical cancer 1 is epithelial.So the generation of gonococcus pili and the infectivity relevant (2,3,32) of this bacterium.
These data show; recombinant pilin can produce the antibody that is incorporated into various pili on the complete gonococcus cell; and this antiserum(antisera) shows functionally active (inhibition bacterial adhesion), and this will protect the people of immunization to resist gonococcus and settle down and infect (32,33).The front reported, was that immunogenic (23,25,28) are arranged with the Bacillus coli cells immunization of the recombinant pilin of expressing plethora artiodactyl shape bacterium, but can not protects the body opposing to attack.Because these results, these investigators no longer adopt the recombinant pilin subunit, and agree with adopting the pili of assembling.Yet the Notes of Key Data described herein has induced a kind of human body of protecting to prevent the immunne response that gonococcus is settled down behind the recombinant expressed pilin purifying.So these data have supported that recombinant pilin is the viewpoint that is used to resist gonococcal candidate vaccine.
As described in embodiment 19, to the N end order-checking of the chimeric I class of meningococcus recombinant pilin.The result that the order-checking of these 35 aminoterminal residues provides is consistent with the dna sequence dna deduced amino acid.The molecular weight of chimeric recombinant pilin (signal peptide is arranged) is 17,659 dalton by mass spectroscopy, with suitable according to 17,676 dalton of aminoacid component prediction.On the contrary, when the chimeric I class of meningococcus recombinant pilin carried out the size exclusion chromatography analysis with stain remover, obtaining apparent molecular weight was 69,480 dalton.Compare with the gonococcus recombinant pilin, the aggegation of the chimeric I class of this prompting meningococcus recombinant pilin.
Describe in detail as embodiment 20, when use elisa assay, the blended antiserum(antisera) of the chimeric I class of meningococcemia recombinant pilin all has very high terminal point titre to meningococcus I class recombinant pilin and the meningococcus cell that carries disease germs mao.As detailed described among the embodiment 20, adjuvant, particularly Stimulon
TMQS-21 is incorporated into the chimeric I class of meningococcus recombinant pilin and the meningococcus cell of the hair that carries disease germs to the antiserum(antisera) of the chimeric I class of meningococcemia recombinant pilin, has produced significantly and has replied.
As described in embodiment 21, immuno-electron microscope shows length (direction) combination of the antibody of the chimeric I class of meningococcemia recombinant pilin along the meningococcus pili.This prompting internal antibody is incorporated into the epi-position that bacterium surface exists.
In embodiment 4, show the antiserum(antisera) identification of anti-gonococcus recombinant pilin and be incorporated into the meningococcus cell of the hair that carries disease germs.Show that in embodiment 22 antiserum(antisera) of the chimeric I class of the meningococcemia of generation recombinant pilin can be incorporated into the gonococcus cell of the hair that carries disease germs.
As described in embodiment 23,, can help prevention meningococcemia in the body with the chimeric I class of cavy meningococcemia recombinant pilin antiserum(antisera) passive immunization children mouse.The level of settling down of bacterium significantly reduces in the animal of accepting this immune serum.In addition, the immunne response that produces with recombinant expressed pilin can be protected the meningococcus of opposing expressing heterologous pilin in vivo.
As described in embodiment 24, with having or not with immunized mice in the chimeric I class of the meningococcus of the Toxins,exo-, cholera recombinant pilin nose, Toxins,exo-, cholera wherein be mutant (L-glutamic acid of its amino acid sites 29 is replaced with Histidine) (CT-CRM, E29H).After the recombinant pilin inoculation of mouse with no adjuvant, the pooled serum of generation has recorded tangible immunne response in antigen ELISA; This is replied by adding mutant CT-CRM, E29H Toxins,exo-, cholera and improving.
As described in embodiment 25, the subcutaneous immunization of mouse contains MPL
TMShow behind the chimeric I class of the meningococcus of the adjuvant recombinant pilin: suppressed Neisseria meningitidis I class bacterial strain settling down at the mouse nasopharynx.
As described in embodiment 26, the Western engram analysis shows the antiserum(antisera) that obtains from the cavy with the chimeric II class of meningococcus recombinant pilin immunization, is incorporated into the full cell lysate of the meningococcus cell (expressing I class or II class pilin) of the hair that carries disease germs.
As described in embodiment 27, inductive is incorporated into the meningococcus cell of homology bacterial isolates at the antiserum(antisera) of the chimeric II class of partially purified meningococcus recombinant pilin.
In sum, these data have been supported recombinant pilin, and particularly chimeric I class of meningococcus and II class recombinant pilin are the viewpoints of the candidate vaccine of anti-Neisseria meningitidis.
The gonococcus recombinant pilin can be used for preparing the vaccine of the disease that protection Mammals opposing gonococcus causes.The chimeric recombinant pilin of meningococcus, meningococcus chimeric I class recombinant pilin and the chimeric II class of meningococcus recombinant pilin can be used for preparing the vaccine of the disease that protection Mammals opposing Neisseria meningitidis causes.
In addition, different Neisseria gonorrhoeae bacterial classifications are resisted in cross protection, can be by carrying out immunization with the vaccine that contains gonococcus recombinant pilin (disease that the opposing of protection Mammals is caused by Neisseria meningitidis); Or with containing the meningococcus recombinant pilin, the vaccine of meningococcus chimeric I class recombinant pilin or the chimeric II class of meningococcus recombinant pilin carries out the disease that the opposing of immunization protection Mammals is caused by gonococcus.
These vaccine compositions comprise the recombinant pilin of a kind of separation and purifying, and this vaccine composition can cause protective immune response in mammalian hosts.
The vaccine that contains recombinant pilin can be mixed with the carrier of acceptable diluent on the immunology or conventionally form, prepares injectable solution or suspension.The antibody horizontal that this vaccine causes can improve by adopting some adjuvant, as Stimulon
TMQS-21 (Aquila Biopharmaceuticals, Inc., Framingham, MA), MPL
TM(3-O-deacylated tRNA monophosphoryl lipid A; RIBI ImmunoChem Research, Inc., Hamiltion, MT), aluminum phosphate, aluminium hydroxide, IL-12 (Genetics Institute, Cambridge, MA) and Toxins,exo-, cholera (wild-type or mutant form, as the L-glutamic acid in amino acid 29 sites by another amino acid, preferably Histidine displacement, U.S. Provisional Patent Application 60/102,430).
Vaccine of the present invention can be by the injection of traditional form, goes into human body as subcutaneous, intraperitoneal or intramuscularly, and in the oral cavity, mucous membrane, nose or vagina give, to induce the initiative immunne response of the disease that protection body opposing gonococcus or meningococcus cause.The dosage that gives is determined by method known to those skilled in the art.By the vaccine of single dose, maybe need to give several times booster dose and give protection.
In order to make the present invention's easy to understand more, list following examples.These embodiment only are for purposes of illustration, do not constitute any restriction to the scope of the invention.
Embodiment
Press the described schemes of people such as Sambrook, used standard molecular biological technique (31).
Embodiment 1
Bacterium and cell cultures
Bacterium and culture condition
The gonococcus isolate derives from Tampa, FL; Ottawa, Canada; Washington, D.C.; Seattle, WA; Rochester, NY; Chapel Hill, NC; And Evanston, IL.The meningococcus isolate derives from Chapel Hill, NC; And Bilthoven, Netherlands.
Bacterium preserve with lyophilized form or-70 ℃ freezing up to use.When growing on solid medium, agar plate is at wet environment and 5% (v/v) CO
237 ℃ of incubators in cultivate.Gonococcus and Neisseria meningitidis are at GC substratum (Difco Laboratories, Detroit, MI) go up growth, this substratum hemoglobin-free, but be added with glucose (400mg/L), glutamine (10mg/L), cocarboxylase (20 μ g/L) and iron nitrate (500 μ g/L).Meningococcal fluid suspension culture thing is grown in 37 ℃ of shaking culture casees (70RPM) in lacking the same substratum of agar.In culture of isolated in the experiment of the meningococcus of mouse nose tissue homogenate, bacterium grows on above-mentioned GC substratum, and contains following blended antibiotic (Difco): colistin sulfate (75 μ g/ml), nystatin (125 μ g/ml), vancomycin (30 μ g/ml) and lactic acid Trimethoprim BP (125 μ g/ml).By the gonococcus that colonial morphology is identified the hair that carries disease germs, single bacterium colony goes down to posterity to keep phenotype every day.Meningococcus cell pili generation state is by (NY) sample of (pH8 30 minutes) carries out the transmission electron microscope assessment for Nanoprobes, Stony Brook to NanoVan dyeing.Intestinal bacteria are grown on SOB agar, SOB agar is made up of following: 20g/L Bacto Tryptones (Difco), 5g/L yeast extract (Difco), 0.6g/L NaCl, 0.2g/L KCl and l% (w/v) agar (pH 7.5), or growth in SOB meat soup (not adding agar).In some experiments, the Bacto Tryptones Hysoy of same amount
TM(Sheffield Products, Norwich NY) replace.
Epithelial cell is cultivated
(ATCC, Beltsville MD) are a kind of epidermoid carcinoma to ME-180 clone, originally are derived from cervical cancer.Make this cell add 10% (v/v) foetal calf serum (Sigma, St.Louis, MO), penicillin G (RPMI1640 (the Gibco BRL of (Gibco BRL), L-Streptomycin sulphate (1mg/mL) (Gibco BRL) and 2mM L-glutaminate of 1000 units/mL), Gaithersburg, MD) in, 37 ℃ of 5% (v/v) CO
2Down growth of wet environment.Division in the every 3-4 of cell days once.
Embodiment 2
Clone and the expression of gonococcus in intestinal bacteria
With the freezing sample of gonococcus bacterial strain Pgh-1 of the hair that carries disease germs source as pilE DNA in the PCR reaction.The primer of the complete pilin of following identification (comprising leader sequence) 3 ' and 5 ' end: 5 ' CCC CGC GCC ATG GAT ACC CTT CAA AAA GGC 3 ' (PILEFWD) (SEQ IDNO:5) and 5 ' GGG CCT GGA TCC GTG GGA AAT CAC TTA CCG 3 ' (PILEREV) (SEQ ID NO:6) used in the amplification of pilE gene.The PCR product that obtains contains a NcoI site at the section start of pilE coding region, contains a BamHI site endways.Consider the clone, this gene is introduced in the NcoI site.Second amino acid whose change that this will cause signal sequence becomes aspartic acid (GAT) from l-asparagine (AAT).Because amino acid 2 is parts of signal peptide, this signal peptide is rived in the normal process of maturation protein, so this change expection does not have any influence to antigenicity or immunogenicity.The PCR product cloning is arrived pCR
TMII TA cloning vector (Invitrogen, Carlsbad, CA) in, connect, be transformed into (Invitrogen) among the intestinal bacteria TOP10F '.Screen bacterium colony containing the dull and stereotyped of 100 μ g/mL penbritins or contain on the flat board of 50 μ g/mL kantlex.From the overnight culture of these transformant, isolate plasmid DNA, and analyze with enzyme EcoRI and NotI restrictive diges-tion.
Contain the segmental clone of correct size insertion to four and make dna sequence analysis, prove conclusively the existence of pilE PCR dna fragmentation.Clone #17, called after pPX1999 is as the source of pilE gene.The plasmid DNA of pPX1999 and pTrcHisA (Invitrogen) is with NcoI and BamHI digestion with restriction enzyme, with this dna fragmentation gel separation, connects and is transformed among the intestinal bacteria TOP 10F '.Screen the amicillin resistance bacterium colony, separate the plasmid DNA of new transformant, carry out the DNA restriction analysis with BamHI and NcoI restriction enzyme.Two clones with correct unrestricted model are made dna sequence analysis.These two clones have correct dna sequence dna, called after pPX2000.
Shake in bottle or the fermentor tank at the SOB that is added with 100 μ g/mL penbritins and 12 μ g/mL tsiklomitsins and grow in order to test the expression of recombinant pilin, make the culture that contains these clones.When shaking bottle, intestinal bacteria grow to A in the 1L substratum
600=0.9-1.0.The isopropyl-(IPTG) that adds final concentration and be 1mM is induced the expression of recombinant pilin, making growth continue 1-4 hour, this moment centrifugal (13,689 * g, 20 minutes, 4 ℃) collecting cell ,-20 ℃ of preservations.For fermentor tank, the overnight culture of a flat board is inoculated into contains the shaking in the bottle of 500mL substratum, continue overnight incubation.Then this liquid culture is inoculated into the Biostat B fermentor tank that contains the 8.9L substratum (Braun Biotech, Allentown, PA) in.When containing HySoy
TMSubstratum when having added the glucose of final concentration 1% (w/v), the growth of bacterium is improved in the fermentor tank.When culture reaches A
600=1.0 o'clock, adding final concentration was the IPTG of 1mM, makes continued growth 1-4 hour, centrifugal then (13,689 * g, 20 minutes, 4 ℃) harvested cell.Abandon nutrient solution ,-20 ℃ of cell precipitations are preserved.After inducing with IPTG, significantly increase the expression of recombinant pilin, induced the back to reach highest level in 3-4 hour.
The sample of inducing culture thing carries out the polyacrylamide gel electrophoresis analysis with sodium laurylsulfonate (SDS-PAGE).Recombinant pilin is observed with Coomassie blue stain, and (Emeryville CA) carries out the checking of Western trace and identifies it for clone #A33020023, Biospacific with gonococcus pili monoclonal antibody specific.
Embodiment 3
Structure contains the gonococcus reorganization pilE plasmid of kalamycin resistance mark
Make up a plasmid, its Amp
RMark Kan
RToken-replacement.Except that in particular the following, with the flow process among the embodiment 2.The pTrcHisA plasmid DNA is carried out the PCR reaction, adopt the TrcFXba primer, 5 ' GGC TCT AGA CTG TCA GAC CAA GTT TAC TC, 3 ' (SEQ ID NO:7) and TrcRXba primer, 5 ' GGC TCT AGA TTG AAG CAT TTA TCA GGG, 3 ' (SEQID NO:8).The sequence encoding XbaI restriction site of band underscore.About 3.5kb PCR product contains pTrcHisA DNA and deducts the penbritin coding region.To pACYC177 plasmid DNA (New England Biolabs, Beverly, MA) carried out another PCR reaction, adopt the KanFXba primer, 5 ' GGC TCT AGA TAA ACAGTA ATA CAA GGG G3 ' (SEQ ID NO:9), with the KanRXba primer, 5 ' GGC TCTAGA TTA GAA AAA CTC ATC GAG C3 ' (SEQ ID NO:10).Equally, the sequence encoding XbaI restriction site of band underscore.The PCR product of about 860bp contains kalamycin resistance gene.Two kinds of PCR products purifying from the sepharose obtains, and with two kinds of DNA of XbaI digestion with restriction enzyme, extracts and couples together.A ligation thing is transformed among the intestinal bacteria TOPl0F ', and a transformation mixture inoculation contains the SOB flat board of 30 μ g/mL kantlex.
To amount to 48 Ka
RBacterium colony is containing streak culture (in duplicate) on the SOB flat board of penbritin or kantlex.As expected, all Kan
RBacterium colony all is amp-S.Because clone's design is symmetric, separates the kantlex inset that has obtained two kinds of orientations.Filter out and original identical clockwise kantlex inset of penbritin gene, be used for further research, be called pZ564.To contain the DNA zone of lacIq gene, trc promotor and multiple clone site among the pZ564, with similar area (also the containing pilE) displacement of pPX2000 plasmid, method is as follows: with SphI and XmnI digestion with restriction enzyme pZ564 and pPX2000.About 2.2kb dna fragmentation of gel-purified pPX2000 and about 2.6kb dna fragmentation of pZ564 couple together, and are transformed among the intestinal bacteria TOP10F '.The correct plasmid that obtains is called pPX2002.When selecting microbiotic when penbritin changes kantlex into, can see similar time course of inductive and recombinant pilin expression level.
Embodiment 4
Clone and expression meningococcus I class pilE in intestinal bacteria
Because the high homology (7) of gonococcus and meningococcus I class pilin DNA and aminoacid sequence, assessed the ability that gonococcus recombinant pilin antiserum(antisera) is incorporated into the pili of meningococcus cell expressing with full cell ELISA.It is 151,100 that this antiserum(antisera) shows the carry disease germs titre of hair cell of the Neisseria meningitidis that is incorporated into bacterial strain H355.
This combination is seemingly at pilin, because the Western trace of this strain whole-cell lysate is shown, has only the single band that moves altogether with pilin can be in conjunction with this antiserum(antisera) (not having display data).Other meningococcus bacterial strain shows low titre in full cell ELISA in a large number, but transmission electron microscope does not prove the existence of pili.According to these data, the I class pilin of decision clone and recombinant expressed Neisseria meningitidis.Originally, adopted the identical strategy of gonococcal pilE.Except that in particular the following, use the flow process among the embodiment 2.
From Neisseria meningitidis bacterial strain H44/76 genomic dna amplification I class pilE, adopt following primer: 5 ' CCC CGC GCC ATG GAC ACC CTT CAA AAA GGT TTT ACC 3 ' (NMFPILE) (SEQID NO:11) and 5 ' GGG CCT GGA TCC GAG TGG CCG TGG AAA ATCACT TAC CGC 3 ' (NMRPILE) (SEQ ID NO:12).As estimating, obtain the PCR product of about 600bp DNA.A PCR reaction product is inserted into pTrcHisA with BamHI and NcoI digestion with restriction enzyme.DNA electrophoresis on sepharose of digestion, the gel-purified dna fragmentation.Then dna fragmentation is coupled together, be transformed among the intestinal bacteria TOP10F '.With BamHI and NcoI restriction enzyme the amicillin resistance clone being carried out the miniplasmids preparation analyzes.The clone who expresses correct restrictive diges-tion pattern is called RZ1142, and plasmid is called pPX2003.
After inducing, when analyzing full cell lysate, observe molecular weight and be about 15,000 daltonian Coomassie blue stain polypeptide with SDS-PAGE.Full cell lysate with four kinds of clones of SDS-PAGE and these clones of Western engram analysis shows, has a kind of albumen, it have suitable mobility and with the responding property of polyclonal antiserum of the complete pili of anti-gonococcus bacterial strain LB2.The I class recombinant pilin length of purifying is 167 amino acid.Yet the expression level of this recombinant pilin is starkly lower than the pPX2000 of growth under the same terms or the level that pPX2003 obtains.The dna sequence dna of analyzing among the reorganization I class pilE shows a large amount of inverted repeats are arranged, the reason of this albumen low expression level in these possible explanation intestinal bacteria.
Embodiment 5
In intestinal bacteria, make up and express gonococcus and the chimeric pilE of meningococcus I class
In order to increase the expression of meningococcus pilin, with preceding 60 the amino acid whose DNA of coding among the pPX2003 (class of meningococcus I described in the embodiment 4 pilE construction) with the suitable regional replacement (SEQ ID NO:4) of pPX2002 (construction of gonococcus pilE described in the embodiment 3 comprises 7 amino acid whose signal peptides).Except that in particular the following, adopt the flow process among the embodiment 2.
In the following manner with of the same area displacement of meningococcus pilE gene conservative 5 ' end regions with Diplococcus gonorrhoeae bacterial strain Pgh-1, following with in the BsmBI site introducing meningococcus pilE gene: from the pPX2003PCR DNA amplification, adopt following primer: 5 ' CCG GCG CGT CTC TCA CGG CGAATG GCC CGG C3 ' is (SEQID NO:13) and 5 ' GGG CCT GGA TCCGAG TGG CCG TGG AAA ATC ACT TAC CGC 3 ' (NMRPILE) (SEQ ID NO:14) and Taq archaeal dna polymerase (CL-1ESPF).The PCR DNA product of expection directly is cloned among the pCR2.1 (Invitrogen) and is transformed into TOP10F ' cell, the plasmid called after pZ578 that obtains.Then, gonococcus pilE is introduced in the BsmBI site, method is as follows.The primer is 5 ' GCA TAA TTC GTG TCG CTC AAG GCG C3, (TRCUPFW) (PILEESPR) (SEQ ID NO:16) and Pfu archaeal dna polymerase of (SEQ ID NO:15) and 5 ' GCC GCG CGT CTC CCG TGA TTC AGGTAA TAC TCG G3 '.5 ' end of pcr amplification pPX2000pilE gene.Gonococcus PCR product and pZ578 with gained digests with BsmBI then, and couples together.The DNA of pcr amplification connection adopts 5 ' GCA TAA TTC GTG TCGCTC AAG GCG C 3 ' (TRCUPFW) (SEQ ID NO:17) and 5 ' GGG CCT GGA TCCGAG TGG CCG TGG AAA ATC ACT TAC CGC 3 ' (NMRPILE) (SEQ ID NO:18) primer again.
DNA PCR product has the size (about 850bp) of expectation, with NcoI and BamHI digestion, obtains the fragment of about 600bp.This fragment of gel separation directly is cloned in the pPX2000 carrier of NcoI and BamHI incision, displacement gonococcus pilE gene.The plasmid that obtains is an amicillin resistance, and mark pPX2004 is used to transform TOP10F '.This transformant analysis shows the chimeric pilE DNA that has expectation.After inducing with IPTG, compare with the meningococcus recombinant pilin amount that pPX2003 expresses, the amount of the chimeric I class of the meningococcus recombinant pilin that construction is expressed significantly increases.Extract and as purification scheme (TMAE Fractogel as described in the embodiment 7 with 1% octyl-β-D-glucopyranoside (OG)
TMPost, 10mM Tfis
TM, pH8.5 contains 0.1% (w/v) Zwittergent
TM3-14) purification of Recombinant gonococcus pilin obtains the chimeric I class of highly purified meningococcus recombinant pilin (yield is about 5mg/g wet cell weight).When analyzing with SDS-PAGE and laser intensity instrument, the purity of this material is greater than 90%.SDS-PAGE shows a main band of about 15,000 dalton's sizes.The length of the chimeric I class of meningococcus recombinant pilin also is 167 amino acid, comprises 7 amino acid whose signal sequences, shows as N-terminal 36 residues order-checking of this purifying protein gained.
Embodiment 6
In intestinal bacteria, make up and express gonococcus and the chimeric pilE of meningococcus II class
The initial stage clone of meningococcus II class pilE comprises from the Neisseria meningitidis bacterial strain FAM18 cellular segregation chromosomal DNA of the hair that carries disease germs and the II class pilE DNA that increases the PCR reaction.The primer of the complete pilin of following identification (comprising leader sequence) 3 ' and 5 ' end is adopted in the amplification of II class pilE gene: 5 ' GCGGCC GCC ATG GAA GCA ATC CAA AAA GGT TTC ACC C3 ' is (SEQID NO:19) and 5 ' GCG GCC GGA TCC GGT CAT TGT CCT TAT TTG GTGCGG C3 ' (PILE2REV) (SEQ ID NO:23) (PILE2FWD).With the strategy similar to embodiment 2, the PCR product that obtains contains a NcoI site at the section start of pilE coding region, contains a BamHI site endways.Consider for the clone, this gene is introduced in the NcoI site.This causes second amino acid whose change of signal sequence, becomes L-glutamic acid (GAA) from Methionin (AAA).As previously mentioned, estimate this variation to antigenicity or immunogenicity without any effect.The PCR product cloning in the pCR2.1 cloning vector (Invitrogen), is connected and is transformed among the intestinal bacteria TOP10F '.Screen bacterium colony containing the dull and stereotyped of 100 μ g/mL penbritins or contain on the flat board of 50 μ g/mL kantlex.From the overnight culture of these transformant, isolate plasmid DNA, and analyze with enzyme EcoRI restriction enzyme.
Clone #8, called after pPX8001 is as the source of pilE gene.The plasmid DNA of pPX8001 and pTrcHisC (Invitrogen) each with NcoI and BamHI digestion with restriction enzyme, the dna fragmentation of gel separation gained connects and is transformed among the intestinal bacteria TOP10F '.Behind the screening amicillin resistance bacterium colony, separate the plasmid DNA of new transformant, carry out the DNA restriction analysis with BamHI and NcoI restriction enzyme.Two clones with correct unrestricted model are made dna sequence analysis.These two clones have correct dna sequence dna, called after pPX8002.
In order to measure the expression of reorganization II class pilin, 10mL is contained these clones' culture, pPX8002 grows in the 50mL pipe, and SOB wherein contains 100 μ g/mL penbritins and 12 μ g/mL tsiklomitsins, up to A
600=1.0.The IPTG that adds final concentration 1mM has induced Recombinant Protein Expression, cultivates and continues 3 hours.When being separated with SDS-PAGE by the full cell lysate of inducing cell and using Coomassie blue stain, do not measure the band of new (inducing).The level of this prompting FAM18 pilE gene product expression is lower than the level of those Coomassie blues (dyeing) identification.When FAM18 pilE is cloned into the pET17b plasmid and be transformed into e. coli bl21 (DE3) pLysS (have or do not have pilE signal sequence), do not measure the obvious expression of recombinant protein.When the II class pilE of two other bacterial strains of Neisseria meningitidis (NmB, 2996) gene clone is gone in identical pTrcHis plasmid and the TOP10F ' expression system, obtain similar result.Determine,, also measure bacterial strain NMB and 2996 and express II class pilin according to PCR and sequencing data.In the separating reaction as template,, adopt the primer (NMFPILE and NMRPILE) of I class and the primer (PILE2FWD and PILE2REV) of II class from some Neisseria meningitidis bacterial strain amplification pilE genes with chromosomal DNA or cell.The PCR product cloning is gone into pTrcHisC and order-checking, or directly order-checking.Carried out the sequence contrast, the sequence of similar H44/76 bacterial strain is decided to be the I class, and the sequence that is similar to the FAM18 bacterial strain is decided to be the II class.Be not to obtain sequence from all amplification bacterial strains.Carried out preliminary classification according to the PCR data.To be those obtain the bacterial strain of correct big or small PCR product with I class primer rather than with II class primer to I class bacterial strain, and II class bacterial strain is those with II class primer rather than obtains the bacterial strain of correct big or small PCR product with I class primer.
According to the test of meningococcus I class pilin, replace with the respective regions of gonococcus bacterial strain Pgh3-1 in the zone of preceding 60 amino acid of the II of will encoding class pilE (conservative aminoterminal zone).The expression of the chimeric pilE of gained is studied in a large amount of escherichia coli expression bacterial strains with various promotor.Experimental strain comprises: PR13 (RNA defective type), BL21 (protease-deficient), KS474 (periplasm protein deficient), AD494 (Novagen, it allows to form disulfide linkage in kytoplasm) and three bacterial strains of TOPP (Stratagene can be used for the non-K-21 bacterial strain of difficult expressing protein).In all experiments, in the SDS-PAGE of Coomassie blue stain, do not measure recombinant protein.Study another expression plasmid pET17b (comprising a T7 promotor) and obtained similar result.
It should be noted that the natural II class ilE gene order among the pPX8002 ends at base 447.Apart from the dna sequence dna in natural meningococcus II class pilE termination site downstream (3 '), Nucleotide 447 to 519 contains reverse tumor-necrosis factor glycoproteins (it may form stem and ring structure).Because stem and ring structure may be effective terminators of transcribing, so should additional lacking of 3 ' sequence (74 base) may influence chimeric II class pilE information transcribing in intestinal bacteria among the hypothesis pPX8002.So all clones afterwards recover this downstream 3 ' end sequence.
Use the respective regions system of gonococcus bacterial strain Pgh3-1 pilE gene to replace the various piece of meningococcus bacterial strain II class pilE gene, purpose is to identify the zone that suppresses expression.Replacement areas is since 5 ' or 3 ' end, and expansion gradually.Also made up the two-way replacement of 5 ' and 3 ' end, up to the interior region of only residual following 84 Nucleotide of natural pilE II class.This zone is also replaced, and the result has rebuild rGC, and as was expected should the clone with similar in appearance to the Coomassie blue stain horizontal expression of pPX2000 recombinant pilin.FAM18 pilE gene with respective regions (bracket in the list) displacement of lower area (number listing) with Pgh3-1 with Nucleotide: single regional replacement be 1-108 (1-108), 1-181 (1-181), 1-294 (1-282), 439-499 (478-553), 379-519 (367-553), 295-519 (283-553), 295-378 (283-366); The dual area displacement is 1-294 (1-282) ﹠amp; 379-519 (367-553), 1-181 (1-181) ﹠amp; 439-499 (478-553), 1-181 (1-181) ﹠amp; 379-519 (367-553), 1-294 (1-282) ﹠amp; 439-499 (478-553).
When expressing these constructions with the pTrcHis expression system in intestinal bacteria TOP10F ', the protein level that two constructions produce can detect with Coomassie blue: first contains the Nucleotide 379-519 displacement of (comprising two sulphur rings and 3 ' overhang); Second displacement that contains Nucleotide 1-181 (comprising conservative 5 ' zone) and 379-519 (comprising two sulphur rings and 3 ' overhang).Can not cause Recombinant Protein Expression because only replace 5 ' zone, also, select this construction (Nucleotide 379-519) and be used for further research because first construction has kept the major part of natural meningococcus pilin sequence.Because meningococcus is obviously different in this zone with the proteic aminoacid sequence of gonococcus, has file (17,18) to point out that this two sulphur ring has experienced significant antigenic variation.So any immunne response at this zone (i.e. two sulphur rings) will show cross reactivity minimum between the meningococcus bacterial strain.Because the gonococcus inset is the twice (39 residues are to 18 residues) of meningococcus two sulphur ring sizes, the apparent molecular weight that the chimeric protein of generation moves on the SDS-PAGE gel is about 19,000 dalton.
The construction process of this mosaic gene is as follows.Amplification pPX8002 (FAM18 II class pilE) obtains 5 ' fragment, and adopt following primer: 5 ' GCG GCC GCC ATG GAA GCA ATC CAA AAA GGT TTCACC C3 ' is (SEQID NO:19) and 5 ' GCC GCG CGT CTC CGA ACCGGA GTT TTG TTT GCC 3 ' (REV-CYS) (SEQ ID NO:20) (PILE2FWD).Obtain gonococcus two sulphur rings (being 3 ' end of gonococcus gene) from the pPX2000 amplification, adopt primer 5 ' CCG GGC CGT CTCGGT TCG GTA AAA TGG TTC TGC 3 ' (FWD-CYS) (SEQ ID NO:21) and 5 ' GGG CCT GGA TCC GTG GGA AAT CAC TTA CCG, 3 ' (PILEREV) (SEQID NO:22).The PCR product that obtains of purifying with restriction enzyme BsmBI digestion, then is connected to form the chimeric pilE of total length respectively, again with primer PILE2FWD and PILEREV amplification.This PCR product digests with restriction enzyme NcoI and BamHI, connects into the pTrcHisC carrier of a similar restriction, is transformed in the TOP10F ' competent cell.
Cultivate transformant, and analyze with restriction enzyme NcoI and BamHI.Four clones have been analyzed with correct big or small inset with restriction enzyme StuI.Wherein, three have correct restriction figure.Measured and had among three clones of correct unrestricted model two sequence.Clone #5 has correct dna sequence dna, called after pPX8017.The nucleotide sequence that this clone contains is listed among the SEQ ID NO:3, wherein Nucleotide 1-378 from Neisseria meningitidis and Nucleotide 379-510 from gonococcus.
In the 50mL pipe, checked expression with the 10mL substratum.Cell is grown (this SOB is added with 100 μ g/ml penbritins and 12 μ g/ml tsiklomitsins) up to A in SOB
600Be about 1.0.Adding final concentration is the IPTG inducing culture thing of 1mM.Allow growth continue 3-4 hour, collect the cell of this time point then by centrifugal (13,689 * g, 20 minutes, 4 ℃) ,-20 ℃ of preservations.For fermentor tank, inoculate the bottle that shakes that contains the 500mL substratum with dull and stereotyped overnight culture or freezing storage liquid, regrowth is spent the night.With this liquid culture inoculate into the Biostat B fermentor tank that contains the 8.9L substratum (Braun Biotech, Allentown, PA) in.When with final concentration being the additional HySoy that contains of 1% (w/v) glucose
TMSubstratum the time, bacterial growth in the fermentor tank improves.When culture reaches A
600During=4.0-6.0, adding final concentration is the IPTG of 1mM, allows the long 2-4 of cell regeneration hour centrifugal then (13,689 * g, 20 minutes, 4 ℃) collecting cell.Abandon nutrient solution, cell precipitation-20 ℃ preservation.By inducing of IPTG, the increase of chimeric II class recombinant pilin is very significant.
In the presence of sodium laurylsulfonate (SDS-PAGE), analyzed derivative culture samples with polyacrylamide gel electrophoresis.Can be observed the chimeric II class of reorganization meningococcus pilin (apparent molecular weight about 19 with Coomassie blue stain, 000 dalton), it identifies by using and makes the Western trace at the polyclonal antiserum of a kind of gonococcus peptide (Glu AlaIle Leu LeuAla Glu Gly Gln Lys Ser Ala Val Thr Glu Tyr Tyr Leu Asn His Gly Lys) (SEQ ID NO:24) and obtain proof that this peptide is positioned at the N-terminal conservative region of II class pilin.The chimeric II class of meningococcus recombinant pilin length is 170 amino acid (comprising signal peptide, SEQ ID NO:4), and wherein amino acid/11-126 is from Neisseria meningitidis, and amino acid/11 27-170 is from gonococcus.
Embodiment 7
Separate and purification of Recombinant gonococcus pilin from intestinal bacteria
With the reorganization gonococcus pilin that obtains in following step purifying the foregoing description 2 and 3.This step can be used for the meningococcus recombinant pilin that obtains among the purifying embodiment 4 equally, and can be used for the chimeric I class of the meningococcus recombinant pilin that obtains among the preliminary purification embodiment 5.Subsequently, described in following embodiment 8, improved the separating step of the chimeric I class of meningococcus recombinant pilin.The colibacillary subcellular fractionation of express recombinant pilin separates and show that this protein binding more may be an inner membrance, because 1% (v/v) Triton on cytolemma
TMX-100 can dissolve this albumen.When having attempted there is 0.05-0.1% (v/v) Triton
TMWhen removing the e. coli protein that depollutes during X-100, recombinant pilin can not be firmly bonded on the ion exchange column when finding to be lower than pH9.5.So, checked the ability of a large amount of stain removers selective dissolution recombinant pilin from the escherichia coli membrane prepared product.
The cell precipitation that will from the lL culture, obtain, (about 5g weight in wet base) is by adding 30mL 10mM Hepes (pH7.2) (Research Organics, Cleveland, OH) and lmM EDTA it is melted, with Microfluidizer cell homogenates device (Microfluidics International Corp., Newton, MA) lysing cell.Centrifugal (12,000 * g, 10 minutes) clarification lysate and precipitation membrane (288,652 * g 1 hour).Costal fold is suspended from 33mL 10mM Hepes (pH7.4), lmM MgCl
2In and in order to a kind of extracting at room temperature of following stain remover 1 hour: (a) Triton
TMX-100 (Calbiochem-Novabiochem International, SanDiego, CA), (b) reductive Triton
TMX-100 (Calbiochern), (c) octyl-β-D-glucopyranoside (OG) (Calbiochem), (d) Zwittergent
TM3-8 (Z3-8) (Calbiochem), (e) Zwittergent
TM3-10 (Z3-10) (Calbiochem), (f) Zwittergent
TM3-12 (Z3-12) (Calbiochem), (g) Zwittergent
TM3-14 (Z3-14) (Calbiochem), (h) Empigen BB
TM(Calbiochem) or (i) Tween
TM80 (ICN, Cleveland, OH).
Empigen BB
TM(1%v/v), Zwittergent
TM3-10 (1%w/v), reductive Triton
TMX-100 (1%v/v), have Zwittergent
TMThe octyl glucoside (1%v/v) of 3-10 (1%w/v) or 3-14 (0.1%w/v) selective extraction has respectively obtained recombinant pilin (containing the most micro-e. coli protein pollutes).Zwittergent
TM3-12 is even 0.1% (w/v) dissolved recombinant pilin and a large amount of e. coli proteins.Triton
TM80 the test any one concentration all can not extract recombinant protein (0.1-1%v/v).
By centrifugal (288,652 * g 1 hour), from undissolved membrane substance, isolate dissolved albumen.Supernatant liquor (containing recombinant pilin) is 4 ℃ of dialysed overnight, dialyzate 10mM Tris
TM(pH 8.5) contain a kind of of following nonionic detergent: (a) 0.1% (w/v) Zwittergent
TM3-14, (b) 1% (w/v) Zwittergent
TM3-10 or (c) 1% (w/v) OG.With the dialysis material at Fractogel
TM(RI) column fractionation separates EMD TMAE-650 (S) for EM Separations Technology, Wakefield, and this post has been used 10mMTris
TM(pH8.5) and each stain remover balance.With contain suitable stain remover with 10mM Tris
TM(pH 8.5), the NaCl linear gradient 0-0.2M that joins comes the albumen of elution of bound.Mix the component, purity assay and the protein content that contain recombinant pilin.In order to increase the purity of recombinant pilin, the blended material is dialysed with initial damping fluid once in a while, and on the TAME post fractional separation for the second time.
The recombinant pilin of selective elution from the post, the SDS-PAGE by Coomassie blue stain makes the laser intensity assay, is highly purified (>90% even matter).When with 1% (w/v) Zwittergent
TM3-10,1% (w/v) OG or 0.1% (w/v) Zwittergent
TMWhen 3-14 extracts with column chromatography for separation, obtain similar result.The yield of recombinant pilin (being the major portion of e. coli protein total amount) is about 10mg/L in the culture that shakes the bottle growth with SOB substratum 1.5L.As recombination bacillus coli (containing pPX2002) HySoym
TMWhen growing in fermentor tank for the substratum on basis, the yield of the recombinant pilin of purifying is increased to about 30mg/L culture, corresponding to every gram cell quality 7mg recombinant pilin.When containing 1% glucose in the fermentor tank, the total recovery of recombinant pilin is increased to about 100mg/L.
The recombinant pilin of purifying (PBS) dialyse with the 10mM sodium phosphate, the 140mMNaCl (pH 7) that contain 0.05% (w/v) Z3-14, sterile filtration, 4 ℃ of preservations or-20 ℃ are frozen.
Embodiment 8
Separate and the chimeric I class of purifying meningococcus recombinant pilin from intestinal bacteria
As described in embodiment 2, large scale culturing contains the Bacillus coli cells of pPX2004 and grows in Biostat B fermentor tank.(about 88 gram weight in wet base intestinal bacteria pPX2004) are resuspended among 440mL l0mMHepes, the 1mM EDTA (pH 7.5) with bacterial cell, and (Microfluidics Corp., Newton MA) breaks with Microfluidizer Model 110Y.The disruptive cell is by centrifugal (6,084 * g, 20 minutes, 10 ℃) clarification.Collect supernatant liquor, by centrifugal (205,471 * g, 1 hour, 10 ℃) separatory membrane component.Precipitation is resuspended to 220mL 10mM Hepes, 1mM MgCl with homogenizer
2, in 1% (w/v) octyl-β-D-glucopyranoside (pH 7.5), and stirring at room 90 minutes.Centrifugal suspension (205,471 * g, 1 hour, 10 ℃).After centrifugal, the supernatant liquor that will contain the chimeric I class of dissolved recombinant pilin is by 0.22 μ Nalgene vacuum filtration film, 4 ℃ of preservations.The pH that regulates octyl glucoside extract with dense NaOH is to pH 8.5, and 200mL TMAE Fractogel then packs into
TM(NJ), this post has been used 25mM Tris for EM Separations Technology, Gibbstown on the post
TM, 0.1% (w/v) Zwittergent
TM3-14 (pH 8.5) balance.With the 400mL level pad of adding uncombined albumen of flush away from the post.The wash-out 25mMTris of recombinant pilin
TM, 0.1% (w/v) Zwittergent
TM3-14 (pH 8.5), the linear gradient NaCl of 10 times of column volumes of joining (0-0.2M NaCl), flow velocity 10.0mL/ minute.Mix the component that contains chimeric I class recombinant pilin, use dH
2O dilutes with 1:1, and packing into, (Bio-Rad, Hercules CA) (have used 10mM NaPO to 100mL 40 μ m ceramic hydroxyl phosphatic rock posts
4, 0.1% (w/v) Zwittergent
TM3-14 (pH 6) balance).With the 200mL level pad of adding uncombined albumen of flush away from the post.The wash-out of chimeric I class recombinant pilin is with containing 0.1% (w/v) Zwittergent
TM10 times of column volume linear gradient NaPO of 3-14
4(10-150mM NaPO
4) liquid, flow velocity 5.0mL/ minute.With SDS-PAGE Analysis and Screening each component, mix the component that those contain chimeric I class recombinant pilin.With the gel of laser intensity instrument detection Coomassie blue stain, the purity of measuring purifying substance is at least 95%.The yield of the chimeric I class recombinant pilin of purifying is about 35mg/g weight in wet base cell.
Embodiment 9
Separate and the chimeric II class of purifying meningococcus recombinant pilin from intestinal bacteria
Unless otherwise indicated, all steps are all carried out at room temperature.The refrigerated Bacillus coli cells is resuspended to 10ml 10mM Hepes (pH 7.2), and 1mM EDTA/g cell is with Microfluidizer cell homogenates device homogenate ruptured cell.Cell lysate is by centrifugal (13,689 * g, 30 minutes) clarification.The supernatant liquor that obtains continues centrifugal (388,024 * g, 30 minutes, 4 ℃).Abandon supernatant liquor, will contain the precipitation-20 ℃ freeze overnight of film.Film precipitation 9mL/ pipe is resuspended to 10mM Hepes (pH 7.2), 1mM MgCl
2In, with 1% (w/v) Zwittergent
TM3-16 (Calbiochem) extracted 1 hour.Centrifugal suspension (388,024 * g, 30 minutes) is used above-mentioned Zwittergent again
TM3-16 extracts the precipitation that obtains.After centrifugal (388,024 * g, 30 minutes), with pellet resuspended in 9mL 50mM Tfis
TMAmong (pH 8.0), the 5mM EDTA, extract with 1% (w/v) N-lauryl sarcosyl (Sigma) room temperature spend the night (slight vibration).This causes the dissolving of the chimeric II class of meningococcus recombinant pilin.Remove insoluble substance by centrifugal (388,024 * g, 30 minutes), abandon it.Adding final concentration in the supernatant liquor that contains the chimeric II class of meningococcus recombinant pilin is the Zwittergent of 1% (w/v)
TM3-14, and use 50mM Tris
TM(pH 8.0), 10mM EDTA, 1%Zwittergent
TM3-14 this material of dialysing spends the night.Get equal portions (1mL, 0.3mg albumen) dialysate and pass through MonoQ
TM(NJ) (5 * 10mm), this post has been used 50mM Tris to post for Pharmacia, Piscataway
TM(pH8.0), 10mM EDTA, 1%Zwittergent
TM3-14 balance, flow velocity are 0.5mL/ minute.Merge and contain chimeric II class recombinant pilin debond material, use 10mM NaPO
4(pH 6.8), 1% (w/v) Zwittergent
TMThe 3-14 dialysed overnight.The purity of this material is about 80%, is used for following embodiment 26 and 27 described researchs.This material is further purified by 1mL hydroxyapatite column (Bio-Rad), and this post has been used 10mMNaPO
4(pH 6.8), 1% (w/v) Zwittergent
TMThe 3-14 balance.With containing 1% (w/v) Zwittergent
TMThe linear gradient 0-0.5M NaPO of 3-14
4The chimeric II proteinoid of the meningococcus of liquid wash-out purifying.With the chimeric II class of SDS-PAGE screening each component recombinant pilin (gel dyes with Coomassie blue or silver).Two kinds of analyses all show, have single polypeptide band, and its molecular weight is about 19,000 dalton.Analyze polyacrylamide gel by laser intensity and show that the purity of this material is greater than 95%.
Embodiment 10
The analytical procedure of gonococcus recombinant pilin
(Pierce, Rockford IL) measure protein content, are standard with BSA with the test of two quinic acid albumen.The purity of protein Preparation thing with coomassie brilliant blue staining polyacrylamide gel (electrophoresis when having SDS) (SDS-PAGE) and is carried out the laser intensity analysis and is determined with Personal Densitometer SI (Molecular Devices).The evaluation of pilin confirms that by the Western trace this monoclonal antibody is (Biospacific) at the purifying pili of gonococcus bacterial strain P9 with embodiment 2 described monoclonal antibodies in the goods.The N terminal sequence of pilin is measured with Applied Biosystems 477A protein sequencing.When the recombinant pilin to purifying carries out the order-checking of N end, often measure two sequences.The main complete pilin of sequence representative comprises 7 amino acid leader sequences.The secondary sequence of forming the 10-20% sample is a recombinant pilin, and it has lacked leader sequence, and sequence is from phenylalanine (the N end residue of ripe gonococcus pilin).For these two kinds of recombinant pilin forms, the result that the order-checking of aminoterminal residue provides is consistent with the sequence of inferring from dna sequence dna.
With Finnagan MAT Lasermat
TM2000 (San Jose CA), with the auxiliary laser desorption ionization of matrix flight time (MALDI-TOF) mass spectrometry, has measured the quality of recombinant pilin.With h-Mb calibrate this instrument to its desired qualities (16,951.5 dalton) 0.01% in.Recombinant pilin and isopyknic cyano group-4-hydroxycinnamic acid matrix (10mg/mL, 70:30 ethyl urea: in 0.1% (v/v) trifluoroacetic acid/water) is mixed.(1 μ L) is stored in the sample phase with this mixed solution of portion, and be air-dry, does the MALDI-TOF mass spectroscopy then.The average data of analyzing (the each analysis is the summation of 10 material feedings) for 15 times are determined the quality of recombinant pilin.Recombinant pilin (band signal peptide) molecular weight of measuring is 18,000 dalton, and is suitable with the molecular weight of estimating according to aminoacid component (17,981).Every batch all measures the small peak that quality is 17,232 dalton (on average).The difference of two kinds of form molecular weight of recombinant pilin (769 dalton) is losing of the first six amino acid of leader sequence (Met Asp Thr Leu Gln Lys) (SEQID NO:2, amino acid/11-6), and its molecular weight is 774 dalton.
Use AG Superose
TM(Pharmacia, Piscataway is UJ) (to contain 0.05% (w/v) Zwittergent for 12 posts
TMThe PBS balance of 3-14), makes size exclusion chromatography, obtain extremely different recombinant pilin apparent molecular weights.Under these conditions, this proteic wash-out position corresponding is 68,899 in molecular weight.This points out this recombinant protein cohesion.Yet, be subjected to the influence of albumen shape to a great extent from the size-exclusion column eluted protein.The result of velocity sedimentation centrefuge experiment shows that the molecular weight of recombinant pilin in solution is about 45,000 dalton.In order to remove stain remover (Zwittergent
TM3-14), recombinant protein is fully dialysed with PBS.The recombinant protein of dialysis shows as solvable, and does not also precipitate at high speed centrifugation (122,000 * g, 1 hour).Do not attempt proof and whether can from recombinant protein, remove stain remover fully.Analyze this material with PBS do gel-filtration, show that this proteic apparent molecular weight is 452,349 dalton.This points out it to experience further cohesion.There is not to determine the quantity of subunit in two kinds of polymers.
452,349 can only be considered as the value of an estimation, are in the micelle because albumen may remain, as do not know whether stain remover is removed fully from sample.In view of recombinant pilin has diluted about 15-30 fact doubly when being mixed with vaccine, it seems that the apparent molecular weight of the recombinant pilin in the vaccine probably is about 450kD.
Embodiment 11
Prepare immune serum from recombinant pilin
(female, 200g) the subcutaneous immunization 20 μ g gonococcus recombinant pilin that is mixed with the purifying of adjuvant has carried out Studies on Immunogenicity by giving cavy.The adjuvant of research is: (a) Stimulon that joins with PBS (pH6)
TMQS-21 (25 μ g/ dosage); (b) aluminum phosphate of joining (Lederle Laboratories, Pearl River, NY, 100 μ g/ dosage) with PBS (pH7); Or it is (c) single with PBS (pH 7).At first, animal is in the 0th, 4 and 8 all immunizations, and is clear in the blood sampling of the 0th, 4,6 and 10 weeks.The analysis of immune response time process shows that the vaccine inoculation of doing in the 8th week for the third time not enhancing immunity is replied, and therefore the research of doing with recombinant pilin afterwards ends at the blood sampling in the 6th week.
Regulate the ability of gonococcus recombinant pilin immunne response in order to study adjuvant, mouse (female, 8 one full year of life, 5 or 10 every group) is collected serum at the albumen of the 0th, 4 and 6 all subcutaneous immunization 1-10 μ g purifying in the 0th, 4,6 and 8 weeks.Carry out the vagina lavation in the 8th week, RPMI 1640 (75 μ L) is instilled into vagina and aspirates 3-4 time.Merge every group of irrigating solution, 50 μ L foetal calf serums are joined in each amalgamation liquid.
For the chimeric I class of meningococcus recombinant pilin, mouse is only accepted immunization in the 0th and 4 weeks, collects serum in the 0th, 4 and 6 weeks.Studied the parenteral immunogenicity of all recombinant pilins in mouse, it is neat to have studied following assistant: (a) Stimulon that joins with PBS (pH6)
TMQS-21 (25 μ g/ dosage); (b) aluminum phosphate of joining (Lederle Laboratories, Pearl River, NY, 100 μ g/ dosage) with PBS (pH7); (c) MPL that joins with PBS (pH7)
TMAluminum phosphate that (50 μ g/ dosage) (d) joins with PBS (pH7) (100 μ g/ dosage) and MPL
TM(50 μ g/ dosage) or single PBS (pH 7) that uses.
For the chimeric II class of meningococcus recombinant pilin, the Stimulon that the 0th and 4 all cavys are accepted 20 μ g albumen and join with PBS (pH6)
TMQS-21 (25 μ g/ dosage) adjuvant is collected serum in the 0th, 4 and 6 weeks.
Assessed capability approach that recombinant expressed pili (the chimeric I class of gonococcus or meningococcus) mucosa immunity-inducing replys and be the salt solution (have or do not have the natural Toxins,exo-, cholera of 1 μ g) that immunization (a) 2.5 μ L in the mouse nose is contained 1 or 10 μ g gonococcus recombinant pilins, or (b) the chimeric I class of 5 μ g recombinant pilin is diluted in 10 μ LPBS (pH 7), there are or do not have 1 μ g mutant CT-CRM, E29H Toxins,exo-, cholera.Give immunization in the 0th, 2 and 3 weeks.
Embodiment 12
The Western engram analysis of anti-gonococcus recombinant pilin immunne response
According to embodiment 11 described schemes, with the gonococcus recombinant pilin immunization cavy of purifying.At first with the Western engram analysis immunization cross the antiserum(antisera) of the cavy of gonococcus recombinant pilin, (not having display data).These traces show that the antiserum(antisera) of anti-gonococcus recombinant pilin discerned a band corresponding to pilin in mao full cell lysate of gonococcus cell that carries disease germs; Band does not dye in the aseptic hair cell lysate of same gonococcus bacterial strain.
From the antiserum(antisera) of the cavy of gonococcus pilin oligomer immunization, obtained to compare data.Obtained the pilin oligomer as above-mentioned (4) by the complete pili that dissociates.Briefly, this comprise with complete pili in 37mM sodium phosphate (pH 12) 4 ℃ the dialysis 48 hours, use 50mM Tris then
TM, 145mMNaCl (pH 8.0) dialysis, centrifugal then (100,000 * g, 1 hour) clarification pilin oligomer.After centrifugal, the pilin oligomer is retained in the supernatant liquor.Compare with the antiserum(antisera) of anti-gonococcus recombinant pilin, pilin oligomer antiserum(antisera) can combine with the cell lysate of the hair that carries disease germs, simultaneously also many other bands (not having display data) of the combined belt and the hair cell lysate that do not carry disease germs.These bands have been represented the pollutent in the pilin oligomer goods, infer that they do not combine with pili.
Embodiment 13
Reorganization gonococcus pilin ELISA
Measured the terminal point titre of the albumen or the bacterial cell of purifying by ELISA.In all ELISA operations, unless otherwise indicated, all cultivated at room temperature 1 hour.The terminal point titre is defined as the extrapolation extent of dilution of light absorption value than blank well (not containing first antibody) big 0.10.For the guinea pig antiserum analysis, the recombinant pilin of purifying is diluted in 0.1M Tris
TM(pH 8), final concentration are 1 μ g/mL.Every part (100 μ L) joins in the hole of microtiter plate (ImmulonI II, Nunc, Naperville IL), 4 ℃ of overnight incubation.With Skanwash 300 titer plate washers (Skatron Instruments, Alexandria, VA), to contain 0.05% (v/v) Tween
TMThe PBS washing of-20 (PBS-T) 5 times.Each seals all holes with the PBS-T that 200 μ L contain 1% (w/v) BSA, washing, and each hole adds a antiserum(antisera) (being diluted in the PBS-T that contains 0.1% (w/v) BSA).The washing titer plate, with 100 μ L couplings the alkaline phosphatase of the anti-cavy IgG of rabbit (heavy chain or light chain) detect bonded first antibody (Zymed Laboratories, South San Francisco, CA), this conjugate is diluted in the 50mM Tris that contains 0.1% (w/v) BSA at 1: 2000
TMIn (pH 8).The washing titer plate, with 100 μ L/ hole phosphoric acid p-nitrophenyls (Sigma) (2mg/mL in the 0.5M diethanolamine, 0.25mM MgCl
2, pH9.8) develop the color.After 30 minutes, add 50 μ L 3N NaOH termination reactions.(MolecularDevices, Sunnyvale CA) read the 405nm absorbancy with Thermomax ELISA plate reader.
The animal of useful recombinant pilin immunization good responsing reaction is all arranged, show as table 1 with antigen ELISA.
The reorganization gonococcus pilin bonded terminal point titre * of table 1 blended anti-gonococcus recombinant pilin guinea pig antiserum and purifying
Prepared product | Immunogen | The terminal point titre | ||
The 0th week | The 4th week | The 6th week | ||
1 | Reorganization Pgh3-1 pilin (goods 1) | ≤100 | 51,345 | 494,805 |
2 | Reorganization Pgh3-1 pilin (goods 2) | 54 | 30,237 | 594,298 |
3 | Reorganization Pgh3-1 pilin (goods 3) | ≤100 | 24,830 | 546,682 |
* three batches of different recombinant pilins are as immunogen.Cavy is in the 0th and 4 all immunizations (subcutaneous injection), and in the blood sampling of the 0th, 4 and 6 weeks.Blended serum is analyzed.
Adjuvant is to the influence of immunne response
In mouse, studied of the influence of following adjuvant: (a) Stimulon that joins with PBS (pH6) to gonococcus recombinant pilin immunne response
TMQS-21; (b) aluminum phosphate of joining with PBS (pH7); (c) MPL that joins with PBS (pH7)
TM(d) aluminum phosphate and the MPL that joins with PBS (pH7)
TMOr it is single with PBS (pH 7).In order to analyze mouse resisting anteserum, the following antigen ELISA flow process of having improved.(Cambridge's microtiter plate MA) is spent the night with the PBS37 ℃ of bag that 100 μ L contain 1 μ g/mL recombinant pilin for Costar EIA/RIA, Coming Costar.With Skantron 300 titer plate washers to contain 0.1% (v/v) Tween
TM-20 PBS wash plate 5 times.With containing 0.1% (w/v) gelatin and 0.02%NaN
3PBS seal each hole.First antibody dilutes with PBS, and this PBS contains 0.1% (w/v) gelatin, 0.05% (v/v) Tween
TM-20 (PBS-TG) and 0.02% (w/v) NaN
3, every part 100 μ L cultivated in microtiter plate 2 hours.After the washing, (Brookwood Biomedical, Birmingham is AL) with PBS-TG and 0.02% (w/v) NaN with the anti-mouse IgG of biotinylated rabbit (Fc zone)
3Dilution in 1: 8000 detects first antibody.Washing is dull and stereotyped, is diluted in PBS-TG and 0.02% (w/v) NaN at 1: 5000 in order to Streptavidin link coupled horseradish peroxidase (Zymed Laboratories) successively
3(cultivating 30 minutes) detects second antibody.Washing is dull and stereotyped, the 0.5mg/mL2 that joins with the 0.1M Citrate trianion that contains 0.03% (v/v) hydrogen peroxide (pH 4.2), 2 '-azine-two-(3-ethyl benzo thiazole phenanthroline-6-sulfonic acid) (ABTS) developed the color 30 minutes, with SLT 340 ATTC microplate reader (SLTLabinstruments, Research Triangle Park NC) monitors at 405nm.Depict data with log-log plot, as above-mentioned definite terminal point titre.
As recombinant pilin MPL
TMDuring for adjuvant, in mouse, obtain humoral immunoresponse(HI), on the order of magnitude, be similar to and use Stimulon
TMQS-21 (table 2A) is observed.The vaginadouche thing of analyzing same animal shows that also the vaginadouche thing of these animals has tangible IgG titre (table 2B).
Table 2A adjuvant influences * body fluid to gonococcus recombinant pilin immunne response:
Antigen ELISA | Full cell ELISA | |||||
Homologous strain | The allos bacterial strain | |||||
Adjuvant | Recombinant pilin | ????Pgh3-1 | ?LB2 | ????#11 | ??T-1 | ?I756 |
?AlPO4 | ????361,260 | ????249,410 | ?93,444 | ?141,622 | ?42,535 | ?89,615 |
?MPLTM | ????1,262,735 | ????902,891 | ?499,223 | ?586,642 | ?165,301 | ?321,340 |
?AlPO4+M ????PLTM | ????1,159,670 | ????265,269 | ?112,856 | ?160,814 | ?41,368 | ?110,162 |
?StimulonT MQS-21 | ????4,915,200 | ????1,053,446 | ?478,338 | ?440,014 | ?111,753 | ?333,341 |
Table 2B adjuvant influences * vaginal douche * * to gonococcus recombinant pilin immunne response
Adjuvant | The recombinant pilin titre | Full cell titer * * * | ||
IgG | IgA | LB2 P+ | LB2 P- | |
AlPO 4 | 1,452 | 262 | 68 | ≤50 |
MPL TM | 6,409 | 26 | 1,128 | 0 |
AlPO 4MPL TM | 938 | 12 | 120 | ≤50 |
Stimulon TMQS-21 | 2,716 | 175 | 311 | 37 |
* Balb/c mouse (5 every group) is at the 0th, 4 and 6 all immunization 10 μ g recombinant pilin, wherein adjuvants such as above-mentioned.Animal is in the blood sampling of the 0th, 4,6 and 8 weeks.Pooled serum to the 8th week performs an analysis.Terminal point titre≤5,000 in the 0th week.
The mixing vaginal douche that * obtained in the 8th week.
* * is with the full cell ELISA of air-dry cell.
P+: the cell of the hair that carries disease germs.P-: the aseptic chalaza variant of mao parental cell deutero-carries disease germs.
Embodiment 14
The full cell ELISA of gonococcus
In full cell ELISA, confirmed, find the cross reaction epi-position of the obvious number that recombinant pilin is expressed in the pili of complete assembling, wherein the antiserum(antisera) of the recombinant pilin of antivenom purification demonstrates the high titre to the gonococcus bacterial strain of numerous expressing heterologous pili.Guinea pig antiserum is measured with following scheme in conjunction with the ability of the gonococcus cell of living.Microtiter plate (Immunolon II) spends the night with the PBS4C cultivation that 100 μ L contain 0.01% (w/v) poly-L-Lysine (Sigma).With the Dacron swab bacteria Agr culture in eve is gathered in the crops among the PBS, the turbidity of suspension is adjusted to A
600=1.0.Remove the polylysine liquid in the microtiter plate, every part 100 μ L bacterial suspension is joined in the hole.With PBS wash plate 5 times, contain PBS (PBS-B) sealing of 1% (w/v) BSA with manual type Nunc washer with 200 μ L.Then, use PBS wash plate 5 times, every part 100 μ L is joined in the hole with the antiserum(antisera) that the PBS that contains 0.1% (w/v) BSA dilutes.After PBS washing 5 times, detect the bonded antiserum(antisera) with the above-mentioned suitable alkaline phosphatase enzyme conjugates of 100 μ L (being diluted among the PBS that contains 0.1%BSA) with 1: 2000.Wash plate is as above-mentioned colour developing and carry out absorbancy reading (30 minutes colour developing).
When analyzing with full cell ELISA, the guinea pig antiserum of anti-recombinant pilin is incorporated into the bacterial isolates of the hair that carries disease germs of each geographic area, but debond is in the cell (table 3) of the corresponding no pili of same gonococcus bacterial strain.
The guinea pig antiserum of the anti-recombinant pilin of table 3 is in conjunction with the terminal point titre * of each bacterial strain gonococcus cell alive
Bacterial strain | The source | Pgh3-1 recombinant pilin (goods 1) | Pgh3-1 recombinant pilin (goods 2) | Pgh3-1 recombinant pilin (goods 3) |
Pgh3-1?P+ | The Pittsburgh | 2,940,971 | ?2,461,272 | ?2,373,641 |
?Pgh3-1?P- | The Pittsburgh | ????<250 | ????<250 | ????<250 |
?LB2?P+ | Unknown | 505,439 | ?481,815 | ?825,517 |
?LB2?P- | Unknown | ????187 | ????34 | ????114 |
?Ⅰ-756P+ | Ontario Lake, Canada | 689,309 | ?713,904 | ?1,026,231 |
?1948?P+ | Romania | 290,367 | ?259,487 | ?325,640 |
?1635?P+ | Panama | 2,714,006 | ≥546,750 | ≥546,750 |
?22714FB?P+ | FortBragg,NC | ????397,763 | ????346,895 | ????498,882 |
????T-1?P+ | Unknown | ????189,490 | ????317,370 | ????272,828 |
?M-2P+ | Unknown | ????124,906 | ????117,734 | ????151,966 |
?3138KP+ | Korea S | ????220,730 | ????179,127 | ????584,044 |
?N-2?P+ | The Norfolk, VA | ????350,210 | ????337,232 | ????435,164 |
?J474B?P+ | Jamaica | ????238,640 | ????205,247 | ????380,970 |
Fresh clinical isolates 52407 P+ | The Tampa, FL | ?598,124 | ?890,678 | ?778,607 |
#11?P+ | Rochester,NY | ????214,673 | ????292,358 | ????385,985 |
?2-57-U17?P+ | Chapel?Hill,NC | ?1,364,126 | ?2,379,267 | ?3,791,263 |
?2-42-U14?P+ | Chapel?Hill,NC | ????1,449,757 | ????1,964,641 | ????11,619,267 |
* three batches of different recombinant pilins are as immunogen.As above-mentioned immunization cavy (subcutaneous irradiation) and blood sampling.Analyze the pooled serum in the 6th week.Terminal point titre≤250 of the 0th all serum.
P+: the cell of the hair that carries disease germs.P-: the aseptic chalaza variant of mao parental cell deutero-carries disease germs.
Carry out the full cell ELISA analysis of anti-recombinant pilin (table 2) mouse resisting anteserum with microtiter plate, wherein use following scheme the bacterium complete drying in the hole.Be harvested among the PBS with the bacteria Agr culture of Dacron swab, and the turbidity of bacterial suspension is adjusted to A eve
600=0.1.Every part of (100 μ L) bacterial suspension joins in the hole 37 ℃ of air-dry plates.After evaporating all liquid, sealing plate is saved in use in 4 ℃.The antigen ELISA flow process of above-mentioned mouse resisting anteserum is adopted in remaining test.Full cell ELISA data (table 2 and 3) prompting, recombinant pilin inductive antibodies is in mao conserved epitope on gonococcus surface that carries disease germs.
Embodiment 15
Induce the mucosal immune response of anti-gonococcus recombinant pilin
Because gonorrhoea is a kind of disease of reproductive tract mucous membrane, the mucosal immunity ability that interesting check mucosa immunity-inducing is replied.Implement as follows.In the 0th, 1 and 2 weeks, with immunized mice in gonococcus recombinant pilin salt solution (1 or 10 μ g/10 μ L) (have or do not have the natural Toxins,exo-, cholera of the 1 μ g) nose.In the 0th, 1 and 2 weeks, immunization recombinant pilin in 5 every group Swiss-Webster mouse noses (have or do not have Toxins,exo-, cholera).Blended serum is analyzed.Terminal point titre<50 in the 0th week.
As shown in table 4, when animal is used the recombinant pilin immunization of no adjuvant, in antigen ELISA, measure significant immunne response (the 0th all titres<300).This is replied by adding natural Toxins,exo-, cholera and is improved.
The reorganization gonococcus pilin bonded terminal point titre of the mixing mouse resisting anteserum of the anti-gonococcus recombinant pilin of table 4 and purifying
Antigen (dosage μ g) | Adjuvant (dosage μ g) | The 22nd day | The 36th day | The 50th day |
Recombinant pilin (1) | Do not have | 1,648 | ?1,287 | ?2,291 |
Recombinant pilin (10) | Do not have | 29,046 | ?20,658 | ?71,067 |
Recombinant pilin (1) | Toxins,exo-, cholera (1) | 4,673 | ?7,526 | ?3,273 |
Recombinant pilin (10) | Toxins,exo-, cholera (1) | 107,011 | ?321,714 | ?280,079 |
Do not have | Toxins,exo-, cholera (1) | ????<300 | ????<300 | ????<300 |
Then, the ELISA with anti-gonococcus bacterial strain FA1090 checks these serum to be incorporated into complete, mao ability of gonococcus cell of carrying disease germs.As above-mentioned with these cells complete drying on microtiter plate.As shown in table 5, in only with pilin, measure low titre (the 0th all titres<300).Adding Toxins,exo-, cholera can improve and the combining of the hair cell that carries disease germs greatly.
The mixing mouse resisting anteserum of the anti-gonococcus recombinant pilin of table 5 and complete, mao gonococcus cell bonded terminal point titre of carrying disease germs
Antigen (dosage μ g) | Adjuvant (dosage μ g) | The 22nd day | The 36th day | The 50th day |
Recombinant pilin (1) | Do not have | ????1,009 | ????852 | ????729 |
Recombinant pilin (10) | Do not have | ????6,009 | ????6,252 | ????5,564 |
Recombinant pilin (1) | Toxins,exo-, cholera (1) | ????1,133 | ????1,456 | ????1,048 |
Recombinant pilin (10) | Toxins,exo-, cholera (1) | 209,522 | ?57,767 | ?38,127 |
Do not have | Toxins,exo-, cholera (1) | ????239 | ????<500 | ????<500 |
Embodiment 16
The gonococcus immunoelectronmicroscopy
Adopt following flow process to observe combining of antiserum(antisera) and the capillary bacterium that carries disease germs.Drip to gold-plated carrying in the net 5 minutes with the recA-in the logarithmic growth later stage a point of mao gonococcus liquid culture that carries disease germs, remove excessive liquid with a filter paper.Carried net 5 minutes with the PSB-S sealing, then with containing 1% fresh gelatin (Fluka, Ronkonkoma, PBS sealing NY) 10 minutes.Then at room temperature, cultivated year net 1-60 minute with the polyclonal antiserum that is diluted in PSB-B.To carry net is immersed in to remove in the PBS-B drop and does not have bonded antibody (4 * 30 seconds).To carry net is immersed in one and is incorporated into the anti-cavy IgG of donkey (Jackson Research Labs, West Grove PA) in the Radioactive colloidal gold of 12nm (to be diluted in PBS-B at 1: 5) 30 minutes, detect the bonded first antibody.As above-mentioned, flushing is carried net 5 times on the PBS-B drop then.Then with containing 1% (v/v) glutaraldehyde (ElectronMicroscopy Sciences, Fort Washington, PBS fixed sample PA) 3 minutes, again with distilled water rinsing 5 * 1 minutes, (NY) (pH 8) slight stain is 30 seconds for NanoProbes, Stony Brook with the NanoVan dye liquor.Make year net contact filter paper remove all liquid, with Zeiss 10C transmission electron microscope, at 15-75,000X checks with the 80kv acceleration voltage.
Shown in immuno-electron microscope (Figure 1A), anti-recombinant pilin antibody is along length (direction) combination of the allos pili fibril on gonococcus surface.This prompting internal antibody will be incorporated into the epi-position that those bacterium surfaces exist.
Embodiment 17
The full cell ELISA of gonococcus recombinant pilin oligomer
In order to identify the biochemistry and the immunological characteristic of those complete pili (or pilin oligomer) recombinant pilin, with the recombinant pilin of purifying phosphoric acid buffer dialysis changing into recombinant pilin oligomer by pH12.Use full cell ELISA, check is incorporated into alive, the gonococcal ability of hair of carrying disease germs by this material (recombinant pilin oligomer) inductive antiserum(antisera).As shown in table 6, induce the antiserum(antisera) of generation to compare with untreated recombinant pilin, the antiserum(antisera) of anti-recombinant pilin oligomer is in conjunction with the various mao gonococcus cells that carry disease germs low-down titre being arranged.This prompting recombinant pilin oligomer has been lost the cross reaction epi-position that is present in usually in a large number on the recombinant pilin.
Table 6pH12 (" oligomerization ") is incorporated into the * that influences of mao gonococcus cell terminal point titre of carrying disease germs to the recombinant pilin guinea pig antiserum
Bacterial strain | Recombinant pilin | Recombinant pilin oligomer * * |
????Ⅰ-756 | ????927,564 | ????16,903 |
????FA-19 | ????107,100 | ????1,982 |
?FA1090(2-57-U17) | ????721,786 | ????6,737 |
????LB2 | ????905,711 | ????4,205 |
????#11 | ????225,602 | ????6,999 |
????#4 | ????288,120 | ????8,104 |
????3138K | ????106,315 | ????5,429 |
????T-1 | ????497,987 | ????42,162 |
????1948 | ????166,864 | ????8,616 |
????J474B | ????576,640 | ????25,002 |
* cavy (4 every group) is in the 0th and 4 weeks, and immunization (subcutaneous injection) 20 μ g recombinant pilin antigens are with 25 μ g Stimulon
TMQS-21 is an adjuvant.Analyze the blended serum in the 6th week.
* at 4 ℃ with the recombinant pilin of sodium phosphate (pH 12) dialysis purifying 48 hours, then with PBS dialysis 24 hours.
Embodiment 18
To sticking the human cervical cancer 1 cell inhibiting
Because pili has mediated gonococcus and combined with the elementary of people's mucomembranous cell, suppress the epithelial ability of these bacterial adhesion so studied recombinant pilin antibody.Selected cervical cancer deutero-ME-180 cell.In addition, minimize, they are grown with the fluid suspension culture thing in order to make the gathering together of capillary bacterium of carrying disease germs in these experiments.This need use the recA of gonococcus bacterial strain Pgh3-1 or 1756
-Derivative is to keep the expression of pili.During in liquid medium, growing 4-5 hour, these recA
-Bacterial strain does not demonstrate significantly and gathers together, and it is more easy that this translates the result.
In these experiments, with ME-180 cell inoculation 8 hole slot slide glasss (Nunc), experiment these cells on same day 80-90% are paved with.With swab with recA
-The overnight culture of gonococcus cell moves among the PBS (being heated to 37 ℃), is used to inoculate the bottle that shakes that contains liquid GC substratum, and this culture medium supplemented has 0.4% (w/v) NaNCO
3, finally reach A
600=0.2.37 ℃ of cell cultures about 4 hours with the 120RPM shaking culture, this moment, culture reached A
600≌ 0.8.Bacterial cell suspension is done dilution in 1: 8 with RPMI 1640, and all holes of second row, 8 hole slots and 300 μ L RPMI 1640 and foetal calf serum were cultivated 1 hour at least.Remove RPMI 1640 confining liquids, add 40 μ L antiserum(antisera)s or RPMI 1640 (no bovine serum), (≈ 8 * 10 to add the bacterial suspension of 260 μ L dilution then
7CFU), 37 ℃/5% (v/v) CO
2Cultivated 1 hour.Contain of RPMI 1640 flushings of the hole slot slide glass of ME180 cell with no antibiotic.Then, the bacterium and the antiserum(antisera) mixed solution of preincubation is added on the ME180 cell 37 ℃ of incubation slide glasss 30 minutes.Remove from the cervical cell individual layer and to contain, wash all holes gently 3 times with RPMI 1640 not in conjunction with the substratum of bacterial cell.After the last flushing, remove hole slot from slide glass, cell is with methyl alcohol fixing 30-60 second, and (VWR Scientific, West Chester PA) dye with the Wright-Giemsa dye liquor.In water, after the decolouring, cover glass is overlayed on each hole.
With oil immersion lens opticmicroscope check slide glass, take the photo in the typical visual field by the people who does not know test sera.Analyze resulting picture by the people who does not know sample type equally.In addition, because mao gonococcus that carries disease germs is incorporated into epithelial monolayers with the form of gathering together, influence comes quantitative measurment by count fine flora rather than bacterium individuality so antiserum(antisera) is to gonococcus cell bonded.Measure the quantity of the capillary flora that carries disease germs with each Kong Quankong finding of ten random scannings.Determined to contain the percentage ratio difference between immune serum and the normal serum hole.Equally, this analysis is independently finished by the investigator who does not know the analytic sample kind.
Initial result shows, carry disease germs hair and aseptic hair cell are with different combining with ME180 sheet monolayer cell in conjunction with pattern.Carry disease germs two strain bacterial strains of hair of gonococcus typically are incorporated into selected epithelial cell in the sheet monolayer cell with bacterial flora collection.On the contrary, corresponding homogenic aseptic hair cell or debond (Pgh3-1) in or present low-level, dispersedly in conjunction with (I756) in epithelial monolayers.So the gathering of bacterium on epithelial monolayers is relevant with the existence of pili.
In addition, having tested anti-Pgh3-1 recombinant pilin guinea pig antiserum suppresses bacterial strain I-756 hair cell that carries disease germs and is incorporated into the ability of ME-180 cell.The analysis of typical picture (comparison diagram 2A (the 6th week) and Fig. 2 B (the 0th week)) shows, the antibody of anti-recombinant pilin the combining of mao gonococcus and cervical epithelial cell of having suppressed significantly to carry disease germs.On the contrary, compare with normal guinea pig serum, the recombinant pilin antiserum(antisera) is to the not influence (not having display data) of combination of the aseptic hair cell of same bacterial strain.Though can not measure bacterium bonded quantity under these conditions, but by counting bonded bacterial flora quantitative analysis adhesion condition when normal or immune serum exist.Determined with this method that (comparing with normal guinea pig serum) anti-recombinant pilin antiserum(antisera) has reduced and be incorporated into epithelial bacterial flora about 60%.
Though this test does not obtain the quantifiable data that is easy to get, may underestimate sero-fast effectiveness by the estimation that the count fine flora obtains.This is because other cell surface composition (as Opa albumen) has mediated this combination, and this can not expect that list just can overcome with anti-recombinant pilin antiserum(antisera).
Embodiment 19
The analytical procedure of the chimeric I class of meningococcus recombinant pilin
With the chimeric meningococcus I of embodiment 10 described analytical class recombinant pilin.As the MALDI-TOF mass spectrograph was measured, the molecular weight subunit of the chimeric I class of meningococcus recombinant pilin was 17,659 dalton, with closely similar according to molecular weight 17,676 dalton of aminoacid component expection.As this albumen Superose
TM12 posts are (to contain 0.05% (w/v) Zwittergent
TMWhen the PBS balance of 3-14) doing the size exclusion chromatography analysis, the apparent molecular weight of chimeric I class recombinant pilin is 69,480 dalton.The apparent molecular weight (68,899 dalton) of the gonococcus recombinant pilin that this and the same terms are analyzed down is basic identical.
Measured the N terminal sequence of the meningococcus I class recombinant pilin of purifying with the Edman edman degradation Edman, result's (deriving from three different samples) is consistent with the protein sequence of estimating.All sequences 35 residues have been measured at least.
Embodiment 20
The chimeric I class of meningococcus recombinant pilin ELISA
With embodiment 13 and 14 described methods, antivenom purification albumen or the sero-fast terminal point titre of bacterial cell have been measured with ELISA.Pooled serum with blood sampling is respectively made ELISA.On the meningococcus cell, make full cell ELISA, this cell heat-killed (56 ℃, 60 minutes) or direct complete drying on microtiter plate.At 620nm, it is 0.1 that cell suspending liquid is diluted to the 620nm absorbancy, gets the hole that every part 100 μ L places microtiter plate.Make each plate 37 ℃ or drying at room temperature, sealing is stored in 4 ℃ up to use.The flow process that changes full cell ELISA is as follows: (1) is diluted in first and second antiserum(antisera)s and contains 0.1% (v/v) Tween
TMAmong the PBS of-20 and 0.1% (w/v) BSA; (2) with Skanwash 300 titer plate washers to contain 0.05% (v/v) Tween
TMDull and stereotyped 5 times of-20 PBS washing.
The cavy of useful chimeric I class recombinant pilin immunization reply well, show as antigen ELISA to see Table 7.
The chimeric I class of the meningococcus recombinant pilin bonded terminal point titre * adjuvant of the chimeric I class of table 7 meningococcus recombinant pilin antiserum(antisera) and purifying:
Blood sampling | Stimulon TM?QS-21 | ????AlPO 4 | Do not have |
The 0th week | ????23 | ????12 | ????32 |
The 4th week | ????26,607 | ????12,067 | ????4,829 |
The 6th week | ????1,519,956 | ????327,539 | ????302,911 |
* cavy (4 every group) is at the chimeric I class of the 0th and 4 all immunizations (subcutaneous injection) 20 μ g recombinant pilin, and wherein the adjuvant of Tian Jiaing is (a) 25 μ g Stimulon
TMThe PBS of QS-21 (pH 6); (b) 100 μ gAlPO
4Salt solution; Or it is (c) single with PBS (pH 7).Animal is in the blood sampling of the 0th, 4 and 6 weeks.Blended serum has been adopted in all analyses.
As shown in table 8, the ELISA of the hair cell that carries disease germs observed significantly reply.
The hair cell bonded terminal point titre * adjuvant that carries disease germs of the chimeric I class of table 8 meningococcus recombinant pilin antiserum(antisera) and meningococcus (bacterial strain H355):
Blood sampling | Sfimulon TM?QS-21 | ????AlPO 4 | Do not have |
The 0th week | ????28 | ????19 | ????53 |
The 4th week | ????1,293 | ????1,052 | ????381 |
The 6th week | ????61,497 | ????25,477 | ????16,467 |
* cell heat-killed.
Adjuvant is to the influence of immunne response
With embodiment 13 described methods, in mouse, studied the influence of adjuvant to the immunne response of the chimeric I class of meningococcus recombinant pilin.As shown in table 9, add Stimulon
TMQS-21 has realized antiserum(antisera) and the most significant the replying of the chimeric I class of meningococcus recombinant pilin bonded.
The chimeric I class of the meningococcus recombinant pilin bonded terminal point titre * adjuvant of the chimeric I class of table 9 meningococcus recombinant pilin antiserum(antisera) and purifying:
Blood sampling | Stimulon TM?QS-21 | ?AlPO 4 | ?MPL TM | ?A1PO 4/MPL TM | Do not have |
The 0th week | ????<50 | ????44 | ????<50 | ????31 | ????<50 |
The 4th week | 44,011 | ?29,925 | ?40,146 | ????110,093 | ????<250 |
The 6th week | 707,084 | ?103,437 | ?284,455 | ????137,686 | ????115, ????022 |
* mouse (10 every group) is at the chimeric I class of the 0th and 4 all immunizations (subcutaneous injection) 10 μ g meningococcuss recombinant pilin, and wherein the adjuvant of Tian Jiaing is (a) 25 μ g Stimulon
TMThe PBS of QS-21 (pH6); (b) 100 μ g AlPO
4Salt solution; (c) 50 μ g MPL
TMPBS (pH 7); (d) 100 μ g AlPO
4With 50 μ g MPL
TMSalt solution; Or it is (e) single with PBS (pH 7).Animal is in the blood sampling of the 0th, 4 and 6 weeks.Blended serum has been adopted in all analyses.
As shown in table 10, add Stimulon
TMQS-21 has also realized antiserum(antisera) and meningococcus the most significant the replying of hair cell bonded of carrying disease germs.
The chimeric I class of table 10 meningococcus recombinant pilin antiserum(antisera) and meningococcus (bacterial strain H355) the hair cell bonded terminal point titre * adjuvant that carries disease germs:
Blood sampling | Stimulon TM?QS-21 | ?AlPO 4 | ?MPL TM | ?AlPO 4/ MPL TM | Do not have |
The 0th week | ????172 | ????146 | ????153 | ????160 | ????<50 |
The 4th week | ????6,088 | ????2,310 | ????4,205 | ????5,647 | ????311 |
The 6th week | 171,718 | ?25,135 | ?52,053 | ?17,039 | ????16,617 |
The cell heat-killed.
Further analyze and shown that the antiserum(antisera) of anti-chimeric I class recombinant pilin can combine with the meningococcus cell of expressing I class pilin (being II class pilin in some experiments).The result who is shown in the table 11 is the evidence of part cross reaction.
Table 11 meningococcus chimeric I class recombinant pilin and the meningococcus hair cell bonded terminal point titre * adjuvant that carries disease germs
Bacterial strain | The type of the pilin of expressing | The 0th day | Stimulon TM?QS-21 | ?AlPO 4 | ?MPL TM |
????H355 | ????Ⅰ | ????409 | ?127,383 | ?41,190 | ?102,987 |
?M982 | ????Ⅰ | ????217 | >36,540 | >36,540 | >36,540 |
?CDC1521 | ???Ⅱ | ????988 | ????2,602 | ????1,345 | ????1,768 |
?FAM18 | ???Ⅱ | ????3,518 | >36,540 | ?26,513 | >36,540 |
* cell is without heat-killed, and directly on microtiter plate dry (room temperature).
Embodiment 21
The chimeric I class of meningococcus recombinant pilin immunoelectronmicroscopy is observed
Following employing transmission electron microscopy has been observed chimeric meningococcus I class recombinant pilin antiserum(antisera) and meningococcus bacterial strain H355 the combining of hair cell of carrying disease germs.Carefully from meningococcus culture in eve, choose a bacterium colony with asepsis ring, place and contain the improved Franz substratum of 0.5-1.0mL [1.3 g/L L-glutamic acid, 20mg/L halfcystine, 10g/L Na
2HPO
47H
2O, 90mg/L KCl, 6g/L NaCl, 2g/L yeast dialysate and replenish with glucose (4g/L), L-glutamic acid (100mg/L), diphosphothiamine (200 μ g/L) and iron nitrate (5mg/L)] the microfuge pipe in.Every part of cell suspension liquid spotting 5 is online inferior to gold-plated year, and wherein every part of cell suspending liquid has been spent 5 minutes, removes excessive liquid with filter paper.Then with the PBS room temperature fixation of bacteria cell 30 minutes that contains 4% (v/v) Paraformaldehyde 96,0.1% (v/v) glutaraldehyde.Carrying net cultivates with following material one by one: (a) PBS-B, 5 minutes; (b) the fresh gelatin PBS of 1% (w/v), 10 minutes; (c) contain the PBS of 0.2M glycine, 5 minutes.As described in the embodiment 16, detect the net that carries of sealing with the chimeric I class of meningococcemia recombinant pilin antiserum(antisera) then.As shown in Figure 3A, the chimeric I class of meningococcemia recombinant pilin antibody is along length (direction) combination of pili.On the contrary, normal serum (the 0th week) does not show has any combination (Fig. 3 B) with pili.
Embodiment 22
The chimeric I class of meningococcus recombinant pilin antiserum(antisera) and gonococcus carry disease germs the cross reactivity of hair cell according to the sequence similarity of meningococcus I class pilin and gonococcus pilin, shown the antiserum(antisera) identification of anti-gonococcus recombinant pilin and be incorporated into the meningococcus cell of the hair that carries disease germs in the foregoing description 4.In the present embodiment, proved that the antiserum(antisera) of the chimeric I class of meningococcemia recombinant pilin is incorporated into the gonococcus cell of the hair that carries disease germs.Table 12 and 13 has been summed up the data of mouse and cavy experiment respectively.
The mouse resisting anteserum of the chimeric I class of meningococcemia recombinant pilin and mao gonococcus cell bonded that carries disease germs
Terminal point titre antigen/adjuvant
The gonococcus bacterial strain | Meningococcus reorganization I class pilin | Gonococcus recombinant pilin+MPL TM | ||||
?Stimulon T? M?QS-21 | ?AlPO 4 | ?MPL TM | ?AlPO 4/M ?pL TM | Do not have | ||
I756 | ?4,527, ????943 | ?79,927 | ?114,958 | ?56,627 | ?57,426 | ????356,936 |
FA1090 | ?531,627 | ?40,406 | ?97,224 | ?31,267 | ?38,122 | ????219,600 |
The guinea pig antiserum of the chimeric I class of table 13 meningococcemia recombinant pilin and mao gonococcus cell bonded terminal point titre antigen/adjuvant that carries disease germs
The gonococcus bacterial strain | Meningococcus reorganization I class pili is white | Gonococcus recombinant pilin+Stimulon TMQS-21 | ||
Stimulon TMQS-21 | AlPO 4 | Do not have | ||
1756 | 301,969 | 122,714 | 78,111 | 46,424 |
FA1090 | 322,311 | 262,422 | 170,842 | 108,094 |
Embodiment 23
With the chimeric I class of meningococcus recombinant pilin antiserum(antisera) passive protection body opposing meningococcus microbemia
The initial young rat model of describing of Saukkonen and Leinonen (34) is a kind of feasibility animal model of estimating vaccine protection body energy meningococcemia microbemia ability.Tested the chimeric I class of meningococcemia recombinant pilin guinea pig antiserum (with Stimulon
TMQS-21 is an adjuvant) protect young rat to resist the ability of microbemia (causing) by the meningococcus bacterial strain of expressing pilin.At the 0th day, the anti-chimeric I class recombinant pilin guinea pig antiserum (the 6th week) of Sprague-Dawley children rat (4-5 age in days) passive immunization (peritoneal injection) 0.1mL (to be diluted in PBS in 1: 5,1: 10 or 1: 20).Control group is accepted 0.1mL normal guinea pig serum (the 0th week) (to be diluted in PBS at 1: 5) injection.After 24 hours, with about 5 * 10
5The 0.1mL of colony-forming unit (cfu) mao meningococcus (bacterial strain H355) that carries disease germs is attacked (peritoneal injection) animal.Attack after 3 hours, put to death animal, get the dilution of equal portions painstaking effort, place on the GC agar plate.Then at 37 ℃ of 5%CO
2The middle cultivation dull and stereotyped 18-24 hour.Enumeration of bacterial colonies is determined bacteremic level then.Compared with a kind of variance t check analysis method and to have accepted immune serum (the 6th week) and organize and accept normal serum (the 0th week) control group.As shown in following table 14, compare with the animal that inoculates with the normal guinea pig seroimmunity, use the animal of the guinea pig antiserum passive immunization of the chimeric I class of specificity meningococcemia recombinant pilin, show the microbemia level and be the minimizing of logarithm level.This difference has statistical significance, p<0.05.
The guinea pig antiserum of the chimeric I class of table 14 meningococcemia recombinant pilin prevents bacteremic ability * in the young rat of attacking with mao meningococcus (bacterial strain H355) that carries disease germs
Blood sampling | Extent of dilution | Cfu mean value ± std |
The 0th week | ????1∶5 | ????4.87±0.18 |
The 6th week | ????1∶5 | ????3.55±0.48** |
The 6th week | ????1∶10 | ????3.63?±0.36** |
The 6th week | ????1∶20 | ????3.98±0.75** |
* is as described in Table 7, from the chimeric I class of the meningococcemia recombinant pilin antiserum(antisera) of cavy acquisition.
**p<0.05。
Cfu ± std=colony-forming unit ± standard deviation
Embodiment 24
Induce the mucosal immune response of the chimeric I class of meningococcemia recombinant pilin
In the 0th, 1 and 2 weeks, give the chimeric I class of immunization meningococcus recombinant pilin salt solution (5 μ g/10 μ L) in the mouse nose, wherein contain or do not contain the cross reaction mutant form Toxins,exo-, cholera (CT-CRM, E29H).As shown in table 15 below, when animal is used the recombinant pilin immunization of no adjuvant, in antigen ELISA, measure significant immunne response.The adding Toxins,exo-, cholera has improved this and has replied.
The chimeric I class of the reorganization meningococcus recombinant pilin bonded terminal point titre * of the chimeric I class of table 15 meningococcemia recombinant pilin mixing mouse resisting anteserum and purifying
Recombinant pilin (no adjuvant) | Recombinant pilin adds CT-CRM | |
Serum IgG IgA | ????6,168 ????490 | ????1,181,871 ????3,940 |
Segmental bronchus washing lotion * * IgG IgA | ????<10 ????<10 | ????580 ????19 |
Nasal cavity washing lotion * * IgG IgA | ????<10 ????12 | ????98 ????236 |
Vaginal douche * * IgG IgA | ????174 ????15 | ????70 ????687 |
* analyzed the pooled serum in the 4th week.The IgG of the 0th all pooled serums and IgA terminal point titre<50.
* is following to carry out lavation:
Segmental bronchus: with 1mL RPMI 1640 lavation lungs 5 times, in sample, add 50 μ L foetal calf serums (FBS) then, centrifugal (2,000 * g * 5 minute) clarification ,-20 ℃ of preservations.Nasal cavity: with 0.5mL RPMI 1640 lavation nostrils once, in sample, add 20 μ L FBS, ℃ preservations then-20.
Vagina: use 0.075mL RPMI 1640 lavation vaginas 5 times, in sample, add 10 μ L FBS ,-20 ℃ of preservations then.
Embodiment 25
Initiatively protect with the chimeric I class of meningococcus recombinant pilin antiserum(antisera) and to resist meningococcal settling down
The first step of the scorching coccus disease of human body endomeninx is that bacterium is settled down in nasopharynx.In this course, it is believed that pili plays a major role in mediating bacterium and epithelial cell tentatively contacts.Many investigators have described the process of bacterial colonisation in the new born animal nasopharynx, but nobody studies (35) with its model of rendeing a service as the test meningococcus vaccine.In order to estimate the present invention, developed with ripe outbreeding mouse as the model of settling down in the meningococcus nose.In the 0th, 4 and 8 weeks, to the chimeric I class of the subcutaneous immunization meningococcus of Swiss-Webster mouse recombinant pilin (with MPL
TMBe adjuvant).In the 10th week, animal intraperitoneal injection 2mg dextran iron (Sigma), and with 10 μ L about 1 * 10
7Attack in mao meningococcus that carries disease germs (the containing 40 μ g dextran iron equally) nose in logarithmic growth mid-term of cfu.Attacked the back the 1st day, half animal is accepted intraperitoneal injection 2mg dextran iron again.Attacked the back the 1st and 2 day, and, measured amount of viable bacteria in the nose by the nose tissue homogenate is inoculated on the GC agar plate that contains the selective antibiotic element.The results are shown in table 16.
Viable count (cfu) * that reclaims in the mouse nose homogenate of table 16 with the meningococcus bacterial strain H355 attack of the hair that carries disease germs
Antigen (dosage μ g) | The cfu/ nose | |
The 1st day * * | The 2nd day * * | |
The full cell of H355 (25) | 1,165 | 67 |
I class recombinant pilin (10) | 6,866 | 63 |
Salt solution | 17,943 | 3,406 |
* all vaccines are with 100 μ g MPL
TM/ agent preparation.Form by 5 mouse for every group.
Fate after attacking in the * nose.
Embodiment 26
The immunne response of the chimeric recombinant pilin of Western engram analysis meningococcemia II class
Adopt as embodiment 11 described flow processs, with the chimeric recombinant pilin immunization of the meningococcus II class cavy of purifying.At first analyzed the antiserum(antisera) (not having display data) that produces with the cavy of the chimeric recombinant pilin immunization of meningococcus II class with the Western blotting.These traces show that the chimeric recombinant pilin antiserum(antisera) of meningococcemia II class has been discerned a band corresponding to pilin in the full cell lysate of mao meningococcus cell that carries disease germs (expressing II class pilin (FAM18) or I class pilin (H355)).On the contrary, the anti-antiserum(antisera) that contains the intestinal bacteria extract of pTrcHis carrier does not react with any pilin band in the Western trace.
Embodiment 27
The chimeric II class of meningococcemia recombinant pilin combines with mao meningococcus cell that carries disease germs
The antiserum(antisera) of the anti-chimeric II class of partially purified meningococcus recombinant pilin shows the meningococcus cell that can be incorporated into homologous strain FAM18, titre>36,450 (titre in the 0th week is 473).
Reference 1.Tennent, J.M., and Mattick, J.S., Fimbriae.Adhesion, Genetics, biogenesis and vaccines, 127-146 page or leaf, P.Klemm, Ed. (FL 1994 for CRC Press, Boca Raton) .2.Strom, M.S., and Lory, S., Ann.Rev.Microbio1., 47,565-596 (1993) .3.Heckels, J.E., Clin.Microbio1.Rev., 2 (Suppl.), S66-73 (1989) .4. United States Patent (USP) 4,702,911,5.Schoo1nik, G.K., J.Exp.Med., 159,1351-1370 (1984) .6.Davies, J.K., Deng the people, Fimbriae.Adhesion, genetics, biogenesis and vaccines, 147-155 page or leaf, P.Klemm, Ed. (FL 1994 for CRC Press, Boca Raton) .7.Aho, E.L., wait the people, Infect.Immun., 65,2613-2620 (1997) .8.Achtman, M., Deng the people, J.Inf.Dis, 165,53-68 (1992) .9.Levine, M.M. waits the people, Fimbriae.Adhesion, genetics, biogenesis and vaccineS, 255-270 page or leaf P.Klemm, Ed. (CRC Press, Boca Raton, FL 1994) .10.Stewart, D.J. waits the people, Aust.Vet.J., 62,153-159 (1985) .11.Tramont, E.C., C1in.Microbiol.ReV., 2 (Suppl.), S74-7 (1989) .12.Boslego, J.W. waits people Vaccine, 9,154-162 (1991) .13.Rothbard, J.B., and Schoolnik, G.K., Adv.Exp.Med.Biol., 185,247-73 (1985) .14.Olafson, R.W., Deng the people, Infect.Immun., 48,336-342 (1985) .15.Seifert, H.S. waits the people, Vaccine, 6.107-109 (1988) .16.Sparling, P.F., Deng the people, Proc.Natl.Acad.Sci.USA, 91,2456-2463 (1994) .17.Tothbard, J.B. waits the people, Proc.Natl.Acad.Sci.USA, 82,915-919 (1985) .18.Forest, K.T., and Tainer, kJ.A., Vaccines 97.Molecular Approaches to the Controlof Infectious Diseases, 167-173 page or leaf F.Brown waits the people, Eds. (NY 1997 for Cold Spring HarborLaboratory Press, Cold Spring Harbor) .19.Robinson, E.N.J., wait the people, Mol.Microbiol., 3,57-64 (1989) .20.Eisentein, B.I., Deng the people, Recombinant DNA vaccines:rationale and stratagies, 89-113 page or leaf R.E.Isaacson, Ed., (Marcel Dekker, Inc., New York, NY 1992) .21.LePPer, A.W., Aust.Vet.J., 65,310-316 (1988) .22.Hull, R.A., wait the people, Infec.Immun., 33,933-938 (1981) .23. European patent 202,260 B124.Hoyne, P.A., wait the people, J.Bact., 174,7321-7327 (1992) .25.Elleman, T.C., Deng the people, Infect.Immun., 51,187-192 (1986) .26.O ' Meara, T.J. waits the people, Immun Cell.biol, 71.473-488 (1993) .27.Emery, D.L., Deng the people, Aust.Vet.J., 61,237-8 (1984) .28.Stewart, D.J. waits the people, Vet.Microbiol., 27,283-93 (1991) .29.Alves, A.M.B., wait the people, American Society for Microbiology, Abstract E-97, the 253rd page of (1997) .30.Meyer, T.F. waits the people, Cell, 30,45-52 (1982) .31.Sambrook, J., Deng the people, Molecular Cloning:A Laboratory Manual, 2nd ed., ColdSpring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989) .32.Stephens, D.S., Clin.Microbiol.Rev., 2 (Suppl.), S104-111 (1989) .33.Tramont, E.C. waits the people, J.Clin.Invest, 68,881-888 (1981) .34.Saukkonen, K. and Leinonen, M., Gonococci and Meningococci, 815-820 page or leaf J.T.Poolman, Ed. (Kluwer Academic Publications, Dordrecht, Netherland, 1986) .35.Salit, I.E., Deng the people, Can.J.Microbiol., 30,1022-1029 (1984).
Sequence Table
<110> American Cyanamid Company
<120> pili proteins containing the recombinant anti-Neisseria gonorrhoeae or Neisseria meningitidis vaccine
<130> 33377-00/PCT
<140>
<141>
<160> 24
<170> PatentIn Ver.2.0
<210> 1
<211> 504
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: chimeric class Ⅰ Neisseria meningitidis and Neisseria gonorrhoeae sequence
<220>
<221> CDS
<222> (1) .. [501)
<400> 1
atg gat acc ctt caa aaa ggc ttt acc ctt atc gag ctg atg att gtg 48
Met Asp Thr Leu Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val
151015
atc gcc atc gtc ggc att ttg gcg gca gtc gcc ctt ccc gcc tac caa 96
Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln
202530
gac tac acc gcc cgc gcg caa gtt tcc gaa gcc atc ctt ttg gcc gaa 144
Asp Tyr Thr Ala Arg Ala Gln Val Ser Glu Ala Ile Leu Leu Ala Glu
35 40 45
ggt caa aaa tca gcc gtt acc gag tat tac ctg aat cac ggc gaa tgg 192
Gly Gln Lys Ser Ala Val Thr Glu Tyr Tyr Leu Asn His Gly Glu Trp
50 55 60
ccc ggc aac aac act tct gcc ggc gtg gca tct tct tca aca atc aaa 240
Pro Gly Asn Asn Thr Ser Ala Gly Val Ala Ser Ser Ser Thr Ile Lys
65 70 75 80
ggc aaa tat gtt aag gaa gtt aca gtc gca aac ggc gtc att acc gcc 288
Gly Lys Tyr Val Lys Glu Val Thr Val Ala Asn Gly Val Ile Thr Ala
85 90 95
aca atg ctt tca agc ggc gta aac aaa gaa atc caa ggc aaa aaa ctc 336
Thr Met Leu Ser Ser Gly Val Asn Lys Glu Ile Gln Gly Lys Lys Leu
100 105 110
tcc ctg tgg gcc aag cgt caa gac ggt tcg gta aaa tgg ttc tgc gga 384
Ser Leu Trp Ala Lys Arg Gln Asp Gly Ser Val Lys Trp Phe Cys Gly
115120125
cag ccg gtt acg cgc acc gac gcc aaa gcc gac acc gtc gcc gcc gcc 432
Gln Pro Val Thr Arg Thr Asp Ala Lys Ala Asp Thr Val Ala Ala Ala
130135140
gcc aag acc gcc gac aac atc aac acc aag cac ctg ccg tca acc tgc 480
Ala Lys Thr Ala Asp Asn Ile Asn Thr Lys His Leu Pro Ser Thr Cys
145150155160
cgc gac gca agt gat gcc agc taa 504
Arg Asp Ala Ser Asp Ala Ser
165
<210> 2
<211> 167
<212> PRT
<213> Artificial Sequence
<400> 2
Met Asp Thr Leu Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val
151015
Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln
202530
Asp Tyr Thr Ala Arg Ala Gln Val Ser Glu Ala Ile Leu Leu Ala Glu
35 40 45
Gly Gln Lys Ser Ala Val Thr Glu Tyr Tyr Leu Asn His Gly Glu Trp
50 55 60
Pro Gly Asn Asn Thr Ser Ala Gly Val Ala Ser Ser Ser Thr Ile Lys
65 70 75 80
Gly Lys Tyr Val Lys Glu Val Thr Val Ala Asn Gly Val Ile Thr Ala
85 90 95
Thr Met Leu Ser Ser Gly Val Asn Lys Glu Ile Gln Gly Lys Lys Leu
100 105 110
Ser Leu Trp Ala Lys Arg Gln Asp Gly Ser Val Lys Trp Phe Cys Gly
115120125
Gln Pro Val Thr Arg Thr Asp Ala Lys Ala Asp Thr Val Ala Ala Ala
130135140
Ala Lys Thr Ala Asp Asn Ile Asn Thr Lys His Leu Pro Ser Thr Cys
145150155160
Arg Asp Ala Ser Asp Ala Ser
165
<210> 3
<21l> 510
<212> DNA
<213> Artificial Sequence
<220>
<223> Artificial Sequence Description: chimeric class II Neisseria meningitidis and Neisseria gonorrhoeae
<220>
<221> CDS
<222> (1) .. (510)
<400> 3
atg gaa gca atc caa aaa ggt ttc acc ctg atc gag ctg atg atc gtc 48
Met Glu Ala Ile Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val
151015
atc gcc atc gtc ggt atc ttg gca gcc gtc gcc ctg ccc gca tac caa 96
Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln
202530
gac tac acc gcg cgc gcc caa atg tcc gaa gcc ctg act ttg gca gaa 144
Asp Tyr Thr Ala Arg Ala Gln Met Ser Glu Ala Leu Thr Leu Ala Glu
35 40 45
ggt caa aaa tcc gca gtg atc gag tat tat tcc gac aac ggc aca ttc 192
Gly Gln Lys Ser Ala Val Ile Glu Tyr Tyr Ser Asp Ash Gly Thr Phe
50 55 60
ccg aac agc aat act tcc gca ggt att gct gcc tct aac gag att aaa 240
Pro Ash Ser Ash Thr Ser Ala Gly Ile Ala Ala Ser Ash Glu Ile Lys
65 70 75 80
ggt aag tat gtg gca tcg gtt aag gtt gaa ggt aat gcc tct gtt gct 288
Gly Lys Tyr Val Ala Ser Val Lys Val Glu Gly Ash Ala Ser Val Ala
85 90 95
tct att acc gct acc atg aac tct agt aat gtg aat aag gac atc aaa 336
Ser Ile Thr Ala Thr Met Asn Ser Ser Asn Val Asn Lys Asp Ile Lys
100 105 110
ggt aaa acc ttg gta ctc gtc ggc aaa caa aac tcc ggt tcg gta aaa 384
Gly Lys Thr Leu Val Leu Val Gly Lys Gln Ash Ser Gly Ser Val Lys
115120125
tgg ttc tgc gga cag ccg gtt acg cgc gac aac gcc gac aac gac gac 432
Trp Phe Cys Gly Gln Pro Val Thr Arg Asp Ash Ala Asp Ash Asp Asp
130135140
gtc aaa gac gcc ggc aac aac ggc atc gaa acc aag cac ctg ccg tca 480
Val Lys Asp Ala Gly Asn Asn Gly Ile Glu Thr Lys His Leu Pro Ser
145150155160
acc tgc cgc gat acg tca tct gat gcc aaa 510
Thr Cys Arg Asp Thr Ser Ser Asp Ala Lys
165170
<210> 4
<211> 170
<212> PRT
<213> Artificial Sequence
<400> 4
Met Glu Ala Ile Gln Lys Gly Phe Thr Leu Ile Glu Leu Met Ile Val
151015
Ile Ala Ile Val Gly Ile Leu Ala Ala Val Ala Leu Pro Ala Tyr Gln
202530
Asp Tyr Thr Ala Arg Ala Gln Met Ser Glu Ala Leu Thr Leu Ala Glu
35 40 45
Gly Gln Lys Ser Ala Val Ile Glu Tyr Tyr Ser Asp Asn Gly Thr Phe
50 55 60
Pro Asn Ser Asn Thr Ser Ala Gly Ile Ala Ala Ser Asn Glu Ile Lys
65 70 75 80
Gly Lys Tyr Val Ala Ser Val Lys Val Glu Gly Asn Ala Ser Val Ala
85 90 95
Ser Ile Thr Ala Thr Met Asn Ser Ser Asn Val Asn Lys Asp Ile Lys
100 105 110
Gly Lys Thr Leu Val Leu Val Gly Lys Gln Asn Ser Gly Ser Val Lys
115120125
Trp Phe Cys Gly Gln Pro Val Thr Arg Asp Asn Ala Asp Asn Asp Asp
130135140
Val Lys Asp Ala Gly Asn Asn Gly Ile Glu Thr Lys His Leu Pro Ser
145150155160
Thr Cys Arg Asp Thr Ser Ser Asp Ala Lys
165170
<210> 5
<211> 30
<212> DNA
<213> Neisseria gonorrhoeae
<400> 5
ccccgcgcca tggataccct tcaaaaaggc 30
<210> 6
<211> 30
<212> DNA
<213> Neisseria gonorrhoeae
<400> 6
gggcctggat ccgtgggaaa tcacttaccg 30
<210> 7
<211> 29
<212> DNA
<213> Neisseria gonorrhoeae
<400> 7
ggctctagac tgtcagacca agtttactc 29
<210> 8
<211> 27
<212> DNA
<213> Neisseria gonorrhoeae
<400> 8
ggctctagat tgaagcattt atcaggg 27
<210> 9
<211> 28
<212> DNA
<213> Neisseria gonorrhoeae
<400> 9
ggctctagat aaacagtaat acaagggg 28
<210> 10
<211> 28
<212> DNA
<213> Neisseria gonorrhoeae
<400> 10
ggctctagat tagaaaaact catcgagc 28
<210> 11
<211> 36
<212> DNA
<213> Ⅰ class Neisseria meningitidis
<400> 11
ccccgcgcca tggacaccct tcaaaaaggt tttacc 36
<210> 12
<211> 39
<212> DNA
<213> Ⅰ class Neisseria meningitidis
<400> 12
gggcctggat ccgagtggcc gtggaaaatc acttaccgc 39
<210> 13
<211> 31
<212> DNA
<213> Ⅰ class Neisseria meningitidis
<400> 13
ccggcgcgtc tctcacggcg aatggcccgg c
31
<210> 14
<211> 39
<212> DNA
<213> Ⅰ class Neisseria meningitidis
<400> 14
gggcctggat ccgagtggcc gtggaaaatc acttaccgc 39
<210> 15
<211> 25
<212> DNA
<213> Neisseria gonorrhoeae
<400> 15
gcataattcg tgtcgctcaa ggcgc 25
<210> 16
<211> 34
<212> DNA
<213> Neisseria gonorrhoeae
<400> 16
gccgcgcgtc tcccgtgatt caggtaatac tcgg 34
<210> 17
<211> 25
<212> DNA
<213> Ⅰ class Neisseria meningitidis
<400> 17
gcataattcg tgtcgctcaa ggcgc 25
<210> 18
<211> 39
<212> DNA
<213> Ⅰ class Neisseria meningitidis
<400> 18
gggcctggat ccgagtggcc gtggaaaatc acttaccgc 39
<210> 19
<211> 37
<212> DNA
<213> Ⅱ class Neisseria meningitidis
<400> 19
gcggccgcca tggaagcaat ccaaaaaggt ttcaccc 37
<210> 20
<211> 33
<212> DNA
<213> Ⅱ class Neisseria meningitidis
<400> 20
gccgcgcgtc tccgaaccgg agttttgttt gcc 33
<210> 21
<211> 33
<212> DNA
<213> Neisseria gonorrhoeae
<400> 21
ccgggccgtc tcggttcggt aaaatggttc tgc 33
<210> 22
<211> 30
<212> DNA
<213> Neisseria gonorrhoeae
<400> 22
gggcctggat ccgtgggaaa tcacttaccg 30
<210> 23
<211> 37
<212> DNA
<213> Ⅱ class Neisseria meningitidis
<400> 23
gcggccggat ccggtcattg tccttatttg gtgcggc 37
<210> 24
<211> 22
<212> PRT
<213> Neisseria gonorrhoeae
<400> 24
Glu Ala Ile Leu Leu Ala Glu Gly Gln Lys Ser Ala Val Thr Glu Tyr
151015
Tyr Leu Asn His Gly Lys
20
...
Claims (42)
1. a vaccine composition is characterized in that, the recombinant expressed Nai Seshi that it comprises separation and purification belongs to pilin, and wherein said vaccine composition can cause protective immune response in the human host.
2. vaccine composition as claimed in claim 1 is characterized in that described pilin is from Diplococcus gonorrhoeae.
3. vaccine composition as claimed in claim 1 is characterized in that described pilin is from Neisseria meningitidis.
4. vaccine composition as claimed in claim 3 is characterized in that, described pilin is a Neisseria meningitidis I class pilin.
5. vaccine composition as claimed in claim 3 is characterized in that, described pilin is a Neisseria meningitidis II class pilin.
6. vaccine composition as claimed in claim 1, it is characterized in that, described pilin is the chimeric recombinant pilin of Diplococcus gonorrhoeae and I class Neisseria meningitidis, described pilin has the aminoacid sequence of SEQ ID NO:2 amino acid/11-167 before processing, or after being processed into maturation protein, have the aminoacid sequence of SEQ ID NO:2 amino acid 8-167 or its aminoacid sequence biologically of equal value.
7. vaccine composition as claimed in claim 1 is characterized in that described vaccine composition also comprises adjuvant, diluent or carrier.
8. vaccine composition as claimed in claim 7 is characterized in that, described adjuvant is selected from: aluminium hydroxide, aluminum phosphate, Stimulon
TMQS-21,3-O-deacylated tRNA monophosphoryl lipid A, IL-12 and wild-type or mutant Toxins,exo-, cholera.
9. the immunization method of an anti-Diplococcus gonorrhoeae is characterized in that, this method comprises the described vaccine composition of claim 2 of administration of human host immune originality dosage.
10. the immunization method of an anti-Diplococcus gonorrhoeae is characterized in that, this method comprises the described vaccine composition of claim 3 of administration of human host immune originality dosage.
11. the immunization method of an anti-Diplococcus gonorrhoeae is characterized in that, this method comprises the described vaccine composition of claim 6 of administration of human host immune originality dosage.
12. the immunization method of an anti-Neisseria meningitidis is characterized in that, this method comprises the described vaccine composition of claim 3 of administration of human host immune originality dosage.
13. the immunization method of an anti-Neisseria meningitidis is characterized in that, this method comprises the described vaccine composition of claim 2 of administration of human host immune originality dosage.
14. the immunization method of an anti-Neisseria meningitidis is characterized in that, this method comprises the described vaccine composition of claim 6 of administration of human host immune originality dosage.
15. a method for preparing vaccine composition is characterized in that the method comprising the steps of: adding dosage is enough to make described vaccine composition to cause protective immune response, the recombinant expressed Nai Seshi genus pilin of separation and purification in the human host.
16. the dna sequence dna of separation and purifying, it is characterized in that, described dna sequence dna is included under the rigorous Southern hybridization conditions of height of standard, dna sequence dna with the dna sequence dna hybridization of coding Diplococcus gonorrhoeae and the chimeric recombinant pilin of I class Neisseria meningitidis, described pilin has the aminoacid sequence of SEQ ID NO:2 amino acid/11-167 before processing, or after being processed into maturation protein, have the aminoacid sequence of SEQIDNO:2 amino acid 8-167 or its aminoacid sequence biologically of equal value.
17. the dna sequence dna of separation and purification as claimed in claim 16, it is characterized in that, described dna sequence dna can be hybridized with the dna sequence dna with SEQ ID NO:1 Nucleotide 1-501 or 22-501 nucleotide sequence under the rigorous Southern hybridization conditions of the height of standard.
18. the dna sequence dna of separation and purifying, it is characterized in that, described dna sequence dna includes the dna sequence dna of coding Diplococcus gonorrhoeae and the chimeric recombinant pilin of I class Neisseria meningitidis, described pilin has the aminoacid sequence of SEQ ID NO:2 amino acid/11-167 before processing, or after being processed into maturation protein, have the aminoacid sequence of SEQ ID NO:2 amino acid 8-167 or its aminoacid sequence biologically of equal value.
19. plasmid, it is characterized in that, described plasmid includes the dna sequence dna of a kind of separation and purifying, this sequence is included under the rigorous Southern hybridization conditions of height of standard, can with the dna sequence dna of the dna sequence dna hybridization of the chimeric recombinant pilin of coding Diplococcus gonorrhoeae and I class Neisseria meningitidis, described pilin has the aminoacid sequence of SEQ ID NO:2 amino acid/11-167 before processing, or after being processed into maturation protein, have the aminoacid sequence of SEQ ID NO:2 amino acid 8-167 or its aminoacid sequence biologically of equal value.
20. plasmid as claimed in claim 19, it is characterized in that, described plasmid is included under the rigorous Southern hybridization conditions of height of standard, can with the dna sequence dna of dna sequence dna hybridization with SEQ ID NO:1 Nucleotide 1-501 or 22-501 nucleotide sequence.
21. a plasmid is characterized in that, described plasmid contains and separates and the coding Diplococcus gonorrhoeae of purifying and the dna sequence dna of the chimeric recombinant pilin of I class Neisseria meningitidis, and this dna sequence dna comprises the described dna sequence dna of claim 18.
22. plasmid as claimed in claim 21 is characterized in that, described plasmid is named as pPX2004 (ATCC 98637).
23. one kind with the described plasmid transformed host cells of claim 19.
24. host cell as claimed in claim 23 is characterized in that, described host cell is the colon bacillus bacterial strain.
25. host cell as claimed in claim 24 is characterized in that, described plasmid is named as pPX2004 (ATCC 98637).
26. method that produces the chimeric recombinant pilin of Diplococcus gonorrhoeae and I class Neisseria meningitidis, it is characterized in that, this method comprises: transform or transfection host cell with the described plasmid of claim 19, and cultivate this host cell under the condition that allows the described chimeric recombinant pilin of host cell expression.
27. a separation and the Diplococcus gonorrhoeae of purifying and the chimeric recombinant pilin of I class Neisseria meningitidis, it is characterized in that, described pilin has the aminoacid sequence of SEQ ID NO:2 amino acid/11-167 before processing, or after being processed into maturation protein, have the aminoacid sequence of SEQ ID NO:2 amino acid 8-167 or its aminoacid sequence biologically of equal value.
28. vaccine composition as claimed in claim 1, it is characterized in that, described pilin is the chimeric recombinant pilin of Diplococcus gonorrhoeae and II class Neisseria meningitidis, described pilin has the aminoacid sequence of SEQ ID NO:4 amino acid/11-170 before processing, or after being processed into maturation protein, have the aminoacid sequence of SEQ ID NO:4 amino acid 8-170 or its aminoacid sequence biologically of equal value.
29. the immunization method of an anti-Diplococcus gonorrhoeae is characterized in that, this method comprises the described vaccine composition of claim 28 of administration of human host immune originality dosage.
30. the immunization method of an anti-Neisseria meningitidis is characterized in that, this method comprises the described vaccine composition of claim 28 of administration of human host immune originality dosage.
31. the dna sequence dna of separation and purifying, it is characterized in that, described dna sequence dna is included under the rigorous Southern hybridization conditions of height of standard, can with the dna sequence dna of the dna sequence dna hybridization of coding Diplococcus gonorrhoeae and the chimeric recombinant pilin of II class Neisseria meningitidis, described pilin has the aminoacid sequence of SEQ ID NO:4 amino acid/11-170 before processing, or after being processed into maturation protein, have the aminoacid sequence of SEQID NO:4 amino acid 8-170 or its aminoacid sequence biologically of equal value.
32. the dna sequence dna of separation as claimed in claim 31 and purifying, it is characterized in that, described dna sequence dna can be hybridized with the dna sequence dna with SEQ ID NO:3 Nucleotide 1-510 or 22-510 nucleotide sequence under the rigorous Southern hybridization conditions of the height of standard.
33. the dna sequence dna of separation and purifying, it is characterized in that, described dna sequence dna includes the dna sequence dna of coding Diplococcus gonorrhoeae and the chimeric recombinant pilin of II class Neisseria meningitidis, described pilin has the aminoacid sequence of SEQ ID NO:4 amino acid/11-170 before processing, or after being processed into maturation protein, have the aminoacid sequence of SEQ ID NO:4 amino acid 8-170 or its aminoacid sequence biologically of equal value.
34. plasmid, it is characterized in that, described plasmid comprises the dna sequence dna of a kind of separation and purifying, this sequence includes under the rigorous Southern hybridization conditions of the height of standard, can with the dna sequence dna of the dna sequence dna hybridization of the chimeric recombinant pilin of coding Diplococcus gonorrhoeae and II class Neisseria meningitidis, described pilin has the aminoacid sequence of SEQ ID NO:4 amino acid/11-170 before processing, or after being processed into maturation protein, have the aminoacid sequence of SEQ ID NO:4 amino acid 8-170 or its aminoacid sequence biologically of equal value.
35. plasmid as claimed in claim 34, it is characterized in that, described plasmid includes under the rigorous Southern hybridization conditions of the height of standard, can with the dna sequence dna of dna sequence dna hybridization with SEQID NO:3 Nucleotide 1-510 or 22-510 nucleotide sequence.
36. a plasmid is characterized in that, described plasmid includes and separates and the coding Diplococcus gonorrhoeae of purifying and the dna sequence dna of the chimeric recombinant pilin of II class Neisseria meningitidis, and this dna sequence dna includes the described dna sequence dna of claim 33.
37. plasmid as claimed in claim 36 is characterized in that, described plasmid is named as pPX8017 (ATCC 207199).
38. one kind with the described plasmid transformed host cells of claim 34.
39. host cell as claimed in claim 38 is characterized in that, described host cell is the colon bacillus bacterial strain.
40. host cell as claimed in claim 39 is characterized in that, described plasmid is named as pPX8017 (ATCC 207199).
41. method that produces Diplococcus gonorrhoeae and the chimeric recombinant pilin of II class Neisseria meningitidis, it is characterized in that, this method comprises: transform or transfection host cell with the described plasmid of claim 34, and cultivate this host cell under the condition that allows the described chimeric recombinant pilin of host cell expression.
42. the Diplococcus gonorrhoeae and the chimeric recombinant pilin of II class Neisseria meningitidis of separation and purifying, described pilin has the aminoacid sequence of SEQ ID NO:4 amino acid/11-170 before processing, or after being processed into maturation protein, have the aminoacid sequence of SEQ ID NO:4 amino acid 8-170 or its aminoacid sequence biologically of equal value.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8340598P | 1998-04-29 | 1998-04-29 | |
US60/083,405 | 1998-04-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1298446A true CN1298446A (en) | 2001-06-06 |
CN1245512C CN1245512C (en) | 2006-03-15 |
Family
ID=22178094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB998056014A Expired - Fee Related CN1245512C (en) | 1998-04-29 | 1999-04-29 | Vaccine containing recombinant pilin and used for resisting neisseria gonorrhoeae or neisseria meningitidis |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1073748A2 (en) |
JP (1) | JP2002527041A (en) |
KR (4) | KR20060118629A (en) |
CN (1) | CN1245512C (en) |
AU (2) | AU3968599A (en) |
BR (1) | BR9910005A (en) |
CA (1) | CA2325055A1 (en) |
IL (1) | IL139311A0 (en) |
WO (1) | WO1999055875A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1942592B (en) * | 2004-04-08 | 2011-10-05 | 昆士兰州卫生部 | Neisseria gonorrhoeae detection |
CN103405760A (en) * | 2013-06-19 | 2013-11-27 | 中国科学院海洋研究所 | Application of edwardsiella tarda pilin FimA |
CN104736563A (en) * | 2012-07-27 | 2015-06-24 | 国家健康与医学研究院 | Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
CN106290849A (en) * | 2015-05-13 | 2017-01-04 | 上海凯创生物技术有限公司 | A kind of meningitis bacterium gold-immunochromatographyreagent reagent for assay box |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0011108D0 (en) * | 2000-05-08 | 2000-06-28 | Microscience Ltd | Virulence gene and protein and their use |
GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
WO2010027729A2 (en) * | 2008-08-25 | 2010-03-11 | Creatv Microtech, Inc. | Gonococcal vaccines |
US9802988B2 (en) * | 2009-05-20 | 2017-10-31 | University Of Maryland, Baltimore | Engineered type IV pilin of Clostridium difficile |
WO2012059593A1 (en) * | 2010-11-05 | 2012-05-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vaccines for preventing meningococcal infections |
JP5991740B2 (en) * | 2012-06-21 | 2016-09-14 | キヤノン株式会社 | License management apparatus, license management method, and program |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL7604311A (en) * | 1975-04-25 | 1976-10-27 | Bactex Inc | METHOD OF INSULATING PILUS CRYSTALS FROM N-GONORRHOEAE AND METHODS OF USING THE CRYSTALS SO OBTAINED. |
EP0049945A3 (en) * | 1980-09-15 | 1982-12-01 | Bactex Incorporated | Determining a hierarchy of piliated organisms and a vaccine prepared from such organisms |
US4443431A (en) * | 1981-05-27 | 1984-04-17 | The United States Of America As Represented By The Department Of Health And Human Services | Neisseria gonorrhoeae vaccine |
EP0177583A4 (en) * | 1984-04-06 | 1988-06-08 | Scripps Clinic Res | A peptide vaccine or diagnostic, and a polypeptide useful therefor. |
CU22302A1 (en) * | 1990-09-07 | 1995-01-31 | Cigb | Codifying nucleotidic sequence for a protein of the external membrane of neisseria meningitidis and the use of that protein in preparing vaccines. |
WO1992013871A1 (en) * | 1991-01-31 | 1992-08-20 | Washington University | Polypeptides and polynucleotides useful for the diagnosis and treatment of pathogenic neisseria |
AU3416693A (en) * | 1991-12-18 | 1993-07-19 | State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University, The | Antigenic preparations that stimulate production of antibodies which bind to the pili of type IV piliated bacteria |
ES2143716T3 (en) * | 1992-06-25 | 2000-05-16 | Smithkline Beecham Biolog | VACCINE COMPOSITION CONTAINING ADJUVANTS. |
WO1994008013A1 (en) * | 1992-10-07 | 1994-04-14 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University | Pilin variants and uses thereof |
US6265567B1 (en) * | 1995-04-07 | 2001-07-24 | University Of North Carolina At Chapel Hill | Isolated FrpB nucleic acid molecule |
-
1999
- 1999-04-29 KR KR1020067022728A patent/KR20060118629A/en not_active Application Discontinuation
- 1999-04-29 WO PCT/US1999/009486 patent/WO1999055875A2/en active Application Filing
- 1999-04-29 BR BR9910005-3A patent/BR9910005A/en not_active IP Right Cessation
- 1999-04-29 IL IL13931199A patent/IL139311A0/en unknown
- 1999-04-29 CA CA002325055A patent/CA2325055A1/en not_active Abandoned
- 1999-04-29 EP EP99922760A patent/EP1073748A2/en not_active Withdrawn
- 1999-04-29 KR KR1020007011991A patent/KR20010043105A/en not_active Application Discontinuation
- 1999-04-29 AU AU39685/99A patent/AU3968599A/en not_active Abandoned
- 1999-04-29 JP JP2000546019A patent/JP2002527041A/en not_active Withdrawn
- 1999-04-29 KR KR1020067022731A patent/KR20060118630A/en not_active Application Discontinuation
- 1999-04-29 CN CNB998056014A patent/CN1245512C/en not_active Expired - Fee Related
- 1999-04-29 KR KR1020067022726A patent/KR20060118628A/en not_active Application Discontinuation
-
2003
- 2003-06-16 AU AU2003204738A patent/AU2003204738B2/en not_active Ceased
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1942592B (en) * | 2004-04-08 | 2011-10-05 | 昆士兰州卫生部 | Neisseria gonorrhoeae detection |
CN104736563A (en) * | 2012-07-27 | 2015-06-24 | 国家健康与医学研究院 | Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
CN103405760A (en) * | 2013-06-19 | 2013-11-27 | 中国科学院海洋研究所 | Application of edwardsiella tarda pilin FimA |
CN106290849A (en) * | 2015-05-13 | 2017-01-04 | 上海凯创生物技术有限公司 | A kind of meningitis bacterium gold-immunochromatographyreagent reagent for assay box |
Also Published As
Publication number | Publication date |
---|---|
KR20010043105A (en) | 2001-05-25 |
KR20060118628A (en) | 2006-11-23 |
WO1999055875A2 (en) | 1999-11-04 |
AU2003204738B2 (en) | 2006-09-14 |
CN1245512C (en) | 2006-03-15 |
CA2325055A1 (en) | 1999-11-04 |
BR9910005A (en) | 2001-01-16 |
IL139311A0 (en) | 2001-11-25 |
JP2002527041A (en) | 2002-08-27 |
EP1073748A2 (en) | 2001-02-07 |
WO1999055875A3 (en) | 2000-04-13 |
KR20060118630A (en) | 2006-11-23 |
KR20060118629A (en) | 2006-11-23 |
AU3968599A (en) | 1999-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5997400B2 (en) | Novel immunogenic composition for prevention and treatment of meningitis disease | |
CN100350972C (en) | Vaccines comprising aluminium adjuvants and histidine | |
Masignani et al. | Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870 | |
EP2265640B1 (en) | Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use | |
CN1159441C (en) | USPA1 and USPA2 antigens of moraxelia catarrhalis | |
CN1306437A (en) | Vaccine | |
JP2010512792A (en) | Novel immunogenic compositions for the prevention and treatment of meningococcal disease | |
CN1674933A (en) | Vaccine composition | |
CN1377415A (en) | Vaccine composition | |
CN1223549A (en) | Moraxella catarrhalis outer membrane protein-106 polypeptide, gene sequence and uses thereof | |
JP2006525330A (en) | Novel immunogenic composition for prevention and treatment of meningococcal disease | |
JPH06169779A (en) | Polynucleotide having nucleotide sequence for coding protein of outer layer film of meningococcus and vaccine composition | |
CN106715464B (en) | Factor H binding protein variants and methods of use thereof | |
CN1352691A (en) | Human complement C3-degrading polypeptide from i(streptococcus pneumoniae) | |
CN1261896A (en) | Surface antigens and proteins useful in compositions for diagnosis and prevention of lyme disease | |
CN1245512C (en) | Vaccine containing recombinant pilin and used for resisting neisseria gonorrhoeae or neisseria meningitidis | |
CN1192101C (en) | Production of the lipidated form of the peptido glycon-associated lipoproteins of gram-negative bacteria | |
CN1350585A (en) | i(Neisseria meningitidis) polypeptide BASBO52 | |
CN1161376C (en) | Major outer membrane protein CD of Moraxella | |
CN1204253C (en) | Neisseria lactoferrin binding protein | |
CN1748791A (en) | Haemorrhagic E, coli 0157:H7 vaccine for human and livestock prevention and preparing method | |
CN1326509A (en) | MOraxella catarrhalis ABSB034 polypeptides and uses thereof | |
CN1890261A (en) | Protein NMB0928 and use thereof in pharmaceutical formulations | |
CN1957085A (en) | Therapeutic peptides | |
CN1330662A (en) | Heliobacter pylori antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |